{
  "letters": 479037,
  "pages": 124,
  "meta": {
    "end_of_period": {
      "year": 2022,
      "month": 12
    },
    "company_name": "Verrica Pharmaceuticals Inc.",
    "major_industry": "Healthcare",
    "mentions_recent_mergers_and_acquisitions": {
      "value": true,
      "elements": [
        {
          "type": "merger_acquisition",
          "page": 1,
          "title": "Filer Classification",
          "data": [
            {
              "key": "category",
              "value": "Large accelerated filer"
            },
            {
              "key": "value",
              "value": ""
            },
            {
              "key": "category",
              "value": "Non-accelerated filer"
            },
            {
              "key": "value",
              "value": "wo"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 17,
          "title": "Patent Strategy and Development for VP-102",
          "data": [
            {
              "key": "Proprietary Technologies",
              "value": "Developing and protecting proprietary technologies related to VP-102."
            },
            {
              "key": "Patent Applications",
              "value": "Filing U.S. and foreign patent applications for cantharidin formulations and applicator devices."
            },
            {
              "key": "Issued Patents",
              "value": "Two U.S. patents for cantharidin formulation and applicators expiring in 2035 and 2038."
            },
            {
              "key": "International Patents",
              "value": "Granted in Australia, Brazil, Canada, Israel, Japan, South Korea, and Mexico."
            },
            {
              "key": "Design Patents",
              "value": "Issued design patent for applicator expiring in 2035, with others pending."
            },
            {
              "key": "Patent Expiry Dates",
              "value": "Utility patents projected to expire from 2034 to 2041."
            },
            {
              "key": "PCT Applications",
              "value": "Nationalized six international PCT patent applications."
            },
            {
              "key": "Additional Patent Risks",
              "value": "Risk of competitors avoiding infringement claims."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 33,
          "title": "Risks Related to Our Financial Position and Capital Needs",
          "data": [
            {
              "key": "net_losses_2022",
              "value": "$24.5 million"
            },
            {
              "key": "net_losses_2021",
              "value": "$35.1 million"
            },
            {
              "key": "accumulated_deficit",
              "value": "$163.5 million"
            },
            {
              "key": "gross_proceeds_IPO",
              "value": "$123.2 million"
            },
            {
              "key": "net_proceeds_follow_on",
              "value": "$55.0 million"
            },
            {
              "key": "product_status",
              "value": "no products approved for commercialization"
            },
            {
              "key": "revenue",
              "value": "never generated any revenue"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "merger_acquisition",
          "page": 82,
          "title": "Regulatory Approvals and Business Growth Risks",
          "data": [
            {
              "key": "Regulatory Approvals",
              "value": "pursue regulatory approvals for VP-102 for the treatment of molluscum, and eventually for the treatment of external genital warts, common warts or any other indications."
            },
            {
              "key": "Product Candidates",
              "value": "seek to discover and develop additional product candidates; seek to in-license or acquire additional product candidates for other dermatological conditions."
            },
            {
              "key": "Commercialization Plans",
              "value": "establish commercialization infrastructure and scale up external manufacturing and distribution capabilities."
            },
            {
              "key": "Economic Conditions",
              "value": "Unfavorable conditions in the economy both in the United States and abroad may negatively affect the growth of the business."
            },
            {
              "key": "Macroeconomic Events",
              "value": "COVID-19 pandemic, rising inflation, U.S. Federal Reserve interest rates, Russia-Ukraine war."
            },
            {
              "key": "Critical Accounting Estimates",
              "value": "The preparation of financial statements requires estimates and assumptions that affect reported amounts of assets and liabilities."
            },
            {
              "key": "Research and Development Costs",
              "value": "rely on third parties for preclinical studies and clinical trials."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 110,
          "title": "Deferred Tax Assets and Liabilities Comparison",
          "data": [
            {
              "key": "Net operating loss carryovers",
              "value": "29,771"
            },
            {
              "key": "Share-based compensation",
              "value": "3,704"
            },
            {
              "key": "Tax credits",
              "value": "2,615"
            },
            {
              "key": "Sec. 174 capitalization",
              "value": "2,465"
            },
            {
              "key": "Amortization",
              "value": "780"
            },
            {
              "key": "Accrued compensation",
              "value": "345"
            },
            {
              "key": "Lease liabilities",
              "value": "383"
            },
            {
              "key": "Other",
              "value": "70"
            },
            {
              "key": "Total deferred tax assets",
              "value": "40,133"
            },
            {
              "key": "Less valuation allowance",
              "value": "(39,732)"
            },
            {
              "key": "Deferred tax asset, net of valuation allowance",
              "value": "401"
            },
            {
              "key": "Right-of-use assets",
              "value": "(362)"
            },
            {
              "key": "Fixed assets",
              "value": "(39)"
            },
            {
              "key": "Total deferred tax liabilities",
              "value": "(401)"
            },
            {
              "key": "Net deferred tax assets",
              "value": "0"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "merger_acquisition",
          "page": 111,
          "title": "Payments and Milestone Achievements under Torii and Lytix Agreements",
          "data": [
            {
              "key": "Agreement Type",
              "value": "Torii Agreement"
            },
            {
              "key": "Payment Received (December 2020)",
              "value": "$0.5 million"
            },
            {
              "key": "Payment Received (April 2021)",
              "value": "$11.5 million"
            },
            {
              "key": "Milestone Payment (July 2022)",
              "value": "$8.0 million"
            },
            {
              "key": "Additional Potential Payments from Torii",
              "value": "$50 million"
            },
            {
              "key": "Collaboration Revenue Recognition",
              "value": "Year ended December 31, 2022"
            },
            {
              "key": "Clinical Supply Agreement Date",
              "value": "March 7, 2022"
            },
            {
              "key": "Collaboration Revenue (2022)",
              "value": "$0.9 million (billed) and $0.1 million (unbilled)"
            },
            {
              "key": "Lytix Agreement Date",
              "value": "August 2020"
            },
            {
              "key": "Upfront Fee to Lytix (2020)",
              "value": "$0.3 million"
            },
            {
              "key": "Regulatory Milestone Payment 1 (May 2022)",
              "value": "$1.0 million"
            },
            {
              "key": "Regulatory Milestone Payment 2 (February 2021)",
              "value": "$2.3 million"
            },
            {
              "key": "Total Obligations under Lytix Agreement",
              "value": "up to $111.0 million"
            },
            {
              "key": "Royalty Rate on Net Sales",
              "value": "low double digits to mid-teens"
            },
            {
              "key": "Subsequent Event Date",
              "value": "February 23, 2023"
            },
            {
              "key": "Shares Sold in Offering",
              "value": "750,000 shares"
            },
            {
              "key": "Pre-Funded Warrants",
              "value": "4,064,814 warrants"
            },
            {
              "key": "Share Price in Offering",
              "value": "$6.75 per share"
            },
            {
              "key": "Gross Proceeds from Offering",
              "value": "$32.5 million"
            },
            {
              "key": "Offering Expenses",
              "value": "approximately $2.3 million"
            }
          ],
          "currency": "USD"
        }
      ]
    },
    "has_leadership_changes": {
      "value": true,
      "elements": [
        {
          "type": "leadership_change",
          "page": 23,
          "title": "FDA Approval Process and Special Protocol Assessment",
          "data": [
            {
              "key": "NDA Evaluation",
              "value": "After evaluating the NDA and related information, the FDA may issue an approval letter or a complete response letter."
            },
            {
              "key": "Complete Response Letter",
              "value": "Contains conditions for securing approval; may require additional documentation or testing."
            },
            {
              "key": "Approval Letter",
              "value": "Authorizes commercial marketing with specific prescribing information."
            },
            {
              "key": "Post-Approval Studies",
              "value": "FDA may require additional studies to assess drug safety post-approval."
            },
            {
              "key": "Changes to Approved Product",
              "value": "Certain changes require further testing and FDA review."
            },
            {
              "key": "Special Protocol Assessment (SPA)",
              "value": "Sponsors can request SPA to agree on Phase 3 trial design."
            },
            {
              "key": "SPA Modifications",
              "value": "SPA can be modified by agreement but does not guarantee trial success."
            },
            {
              "key": "Orange Book Listing",
              "value": "Applicants must list patents with the FDA when seeking NDA approval."
            },
            {
              "key": "Paragraph IV Certification",
              "value": "Required for ANDA seeking approval of a generic drug."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Employment Agreement by and between the Registrant and Gary Goldenberg",
          "data": [
            {
              "key": "Agreement Date",
              "value": "August 1, 2020"
            },
            {
              "key": "Incorporated By Reference",
              "value": "Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K"
            },
            {
              "key": "Filing Date",
              "value": "March 2, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Employment Agreement by and between the Registrant and Christopher Hayes",
          "data": [
            {
              "key": "Agreement Date",
              "value": "February 27, 2020"
            },
            {
              "key": "Incorporated By Reference",
              "value": "Exhibit 10.24 to the Registrant’s Annual Report on Form 10-K"
            },
            {
              "key": "Filing Date",
              "value": "March 2, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 116,
          "title": "Amended and Restated Non-Employee Director Compensation Policy",
          "data": [
            {
              "key": "Adopted Date",
              "value": "February 24, 2022"
            },
            {
              "key": "Incorporated By Reference",
              "value": "Exhibit 10.27 to the Registrant’s Annual Report on Form 10-K"
            },
            {
              "key": "Filing Date",
              "value": "March 2, 2022"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 118,
          "title": "Board of Directors and Officers Signatures",
          "data": [
            {
              "key": "Name",
              "value": "Ted White"
            },
            {
              "key": "Title",
              "value": "President, Chief Executive Officer and Director (Principal Executive Officer)"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "P. Terence Kohler, Jr."
            },
            {
              "key": "Title",
              "value": "(Principal Financial Officer and Principal Accounting Officer)"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Paul B. Manning"
            },
            {
              "key": "Title",
              "value": "Chairman of the Board of Directors"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Sean Stalfort"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Craig Ballaron"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Mark Prygocki"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Lawrence Eichenfield"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Name",
              "value": "Diem Nguyen"
            },
            {
              "key": "Title",
              "value": "Director"
            },
            {
              "key": "Date",
              "value": "March 6, 2023"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "leadership_change",
          "page": 122,
          "title": "CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER",
          "data": [
            {
              "key": "Date",
              "value": "6th day of March, 2023"
            },
            {
              "key": "Company",
              "value": "Verrica Pharmaceuticals Inc."
            },
            {
              "key": "Principal Executive Officer",
              "value": "Ted White"
            },
            {
              "key": "Principal Financial Officer",
              "value": "P. Terence Kohler, Jr."
            },
            {
              "key": "Annual Report Fiscal Year End",
              "value": "December 31, 2022"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_layoffs": {
      "value": true,
      "elements": [
        {
          "type": "layoff",
          "page": 69,
          "title": "Risks Related to Employee Retention and Misconduct",
          "data": [
            {
              "key": "Executive Officers Impact",
              "value": "The loss of executive officers or key employees may impede development and commercialization objectives."
            },
            {
              "key": "Challenges in Replacement",
              "value": "Replacing key personnel may be difficult due to limited individuals in the industry with necessary skills."
            },
            {
              "key": "Competition for Personnel",
              "value": "Intense competition exists for hiring from a limited talent pool in pharmaceuticals and biotechnology."
            },
            {
              "key": "Consultant Commitment Issues",
              "value": "Consultants may have commitments that limit their availability to the company."
            },
            {
              "key": "Employee Numbers",
              "value": "As of December 31, 2022, there were 22 full-time employees."
            },
            {
              "key": "Anticipated Growth",
              "value": "Significant growth in employees and operations is expected as development progresses."
            },
            {
              "key": "Management Challenges",
              "value": "Limited experience in managing anticipated growth may hinder effective operational expansion."
            },
            {
              "key": "Misconduct Risk",
              "value": "Risk exists that employees and contractors may engage in misconduct or non-compliance with regulations."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Misconduct can result in regulatory sanctions impacting reputation and operations."
            },
            {
              "key": "Penalties for Non-Compliance",
              "value": "Potential penalties include fines, imprisonment, and exclusion from government healthcare programs."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_executive_compensation": {
      "value": true,
      "elements": [
        {
          "type": "executive_compensation",
          "page": 13,
          "title": "Phase 2 CARE-I Trial Details",
          "data": [
            {
              "key": "study",
              "value": "Phase 2 CARE-I Trial n=105, Total Part A: 18/Part B:87"
            },
            {
              "key": "treatment",
              "value": "VP-102"
            },
            {
              "key": "design",
              "value": "Randomized, placebo-controlled, multi-center"
            },
            {
              "key": "objective",
              "value": "To evaluate safety and efficacy over four treatments"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 13,
          "title": "CARE-2 Phase 3 Trial Plans",
          "data": [
            {
              "key": "description",
              "value": "End of Phase 2 meeting held with FDA in May 2021"
            },
            {
              "key": "initiation_date",
              "value": "Second half of 2024"
            },
            {
              "key": "trial_structure",
              "value": "Two identical trials and a pharmacokinetics study"
            },
            {
              "key": "focus",
              "value": "Efficacy and safety of VP-102 in subjects with EGW"
            },
            {
              "key": "total_participants",
              "value": "Approximately 410 subjects per trial"
            },
            {
              "key": "aggregate_participants",
              "value": "Approximately 532 subjects"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 14,
          "title": "Clinical Study Results",
          "data": [
            {
              "key": "Clinical Study Reporting Date",
              "value": "June 2019"
            },
            {
              "key": "Cohort 1 Dosing Regimen",
              "value": "14 days"
            },
            {
              "key": "Cohort 2 Dosing Regimen",
              "value": "21 days"
            },
            {
              "key": "Applications",
              "value": "up to 4 applications of 24-hour treatment"
            },
            {
              "key": "Wart Paring",
              "value": "allowed in Cohort 2"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 18,
          "title": "Lytix License Agreement",
          "data": [
            {
              "key": "License Fee (Initial Payment)",
              "value": "$250,000"
            },
            {
              "key": "Additional Payments (February 2021)",
              "value": "$2.25 million"
            },
            {
              "key": "Additional Payments (May 2022)",
              "value": "$1.0 million"
            },
            {
              "key": "Contingent Payments",
              "value": "Up to $111.0 million based on specified milestones"
            },
            {
              "key": "Royalty Rate",
              "value": "Low double digits to mid-teens"
            },
            {
              "key": "Royalty Expiration",
              "value": "On a country-by-country and product-by-product basis on the later of the expiration or abandonment of the last patent covering VP-315 and expiration of regulatory exclusivity"
            },
            {
              "key": "Sublicensee Royalties Sharing Rate",
              "value": "Initially 50%, decreasing based on development stage of VP-315"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 101,
          "title": "Fair Value Measurement and Stock-Based Compensation",
          "data": [
            {
              "key": "Fair Value Measurement",
              "value": "Guidance on the development and disclosure of fair value measurements classified into Level 1, Level 2, and Level 3."
            },
            {
              "key": "Comprehensive Loss",
              "value": "The change in equity of a business enterprise from transactions and circumstances from non-owner sources."
            },
            {
              "key": "Stock-Based Compensation",
              "value": "Accounts for stock-based compensation awards under ASC 718, using Black-Scholes to value stock options."
            },
            {
              "key": "Expected Term",
              "value": "Assumes the expected term of options based on historical data."
            },
            {
              "key": "Volatility",
              "value": "Estimated based on historical volatility of peer companies."
            },
            {
              "key": "Risk-Free Interest Rate",
              "value": "Based on U.S. Treasury notes for the term approximating the expected life of the option."
            },
            {
              "key": "Dividend Yield",
              "value": "Expected dividend yield is zero as the company has never paid cash dividends."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 105,
          "title": "Accrued Expenses and Other Current Liabilities Comparison",
          "data": [
            {
              "key": "Compensation and related costs",
              "value": "1399"
            },
            {
              "key": "Clinical trials and drug development",
              "value": "974"
            },
            {
              "key": "Construction in process",
              "value": "167"
            },
            {
              "key": "Professional fees",
              "value": "58"
            },
            {
              "key": "Machinery and equipment",
              "value": "57"
            },
            {
              "key": "Interest expense",
              "value": "0"
            },
            {
              "key": "Other accrued expenses and other current liabilities",
              "value": "0"
            },
            {
              "key": "Total accrued expenses and other current liabilities",
              "value": "2055"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 106,
          "title": "Stockholders’ Equity and Stock-Based Compensation",
          "data": [
            {
              "key": "Authorized shares of common stock",
              "value": "200,000,000"
            },
            {
              "key": "Par value per share",
              "value": "$0.0001"
            },
            {
              "key": "Voting entitlement",
              "value": "One vote per share"
            },
            {
              "key": "Dividends",
              "value": "Entitled when legally available and declared by the Board"
            },
            {
              "key": "Follow-on public offering (2021) shares sold",
              "value": "2,033,899 shares"
            },
            {
              "key": "Follow-on public offering (2021) price per share",
              "value": "$14.75"
            },
            {
              "key": "Net proceeds from 2021 offering",
              "value": "$28.1 million"
            },
            {
              "key": "Follow-on public offering (2022) shares sold",
              "value": "13,575,000 shares"
            },
            {
              "key": "Follow-on public offering (2022) price per share",
              "value": "$2.10"
            },
            {
              "key": "Net proceeds from 2022 offering",
              "value": "$26.9 million"
            },
            {
              "key": "2018 Equity Incentive Plan effective date",
              "value": "June 2018"
            },
            {
              "key": "Number of shares reserved under 2018 Plan",
              "value": "3,738,199 shares"
            },
            {
              "key": "Shares available for grant under 2018 Plan (as of 2022)",
              "value": "3,108,393 shares"
            },
            {
              "key": "Vesting timeline for stock options",
              "value": "25% after 12 months, 75% ratable over 36 months"
            },
            {
              "key": "Maximum term of stock options",
              "value": "10 years"
            },
            {
              "key": "Grant date fair value determination method",
              "value": "Black-Scholes option-pricing model"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Stock Options Activity Summary",
          "data": [
            {
              "key": "Outstanding as of December 31, 2020",
              "value": "2901908"
            },
            {
              "key": "Options granted",
              "value": "1222786"
            },
            {
              "key": "Exercised",
              "value": "-44041"
            },
            {
              "key": "Forfeited",
              "value": "-462617"
            },
            {
              "key": "Expired",
              "value": "-174219"
            },
            {
              "key": "Outstanding as of December 31, 2021",
              "value": "3443817"
            },
            {
              "key": "Options granted",
              "value": "1137936"
            },
            {
              "key": "Exercised",
              "value": "0"
            },
            {
              "key": "Forfeited",
              "value": "-468335"
            },
            {
              "key": "Expired",
              "value": "-180639"
            },
            {
              "key": "Outstanding as of December 31, 2022",
              "value": "3932779"
            },
            {
              "key": "Options vested and exercisable as of December 31, 2022",
              "value": "2272105"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 107,
          "title": "Restricted Stock Awards Summary",
          "data": [
            {
              "key": "on-vested as of December 31, 2020",
              "value": "475,000"
            },
            {
              "key": "Forfeitures",
              "value": "(50,000)"
            },
            {
              "key": "on-vested as of December 31, 2021",
              "value": "425,000"
            },
            {
              "key": "on-vested as of December 31, 2022",
              "value": "425,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Stock-Based Compensation Breakdown",
          "data": [
            {
              "key": "Category: Research and development",
              "value": "$1,460"
            },
            {
              "key": "Category: General and administrative",
              "value": "$3,525"
            },
            {
              "key": "Category: Total stock-based compensation",
              "value": "$4,985"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 108,
          "title": "Finance Lease Cost",
          "data": [
            {
              "key": "Amortization ROU assets",
              "value": "$4"
            },
            {
              "key": "Operating lease costs",
              "value": "$369"
            },
            {
              "key": "Short-term lease costs",
              "value": "$7"
            },
            {
              "key": "Total operating lease",
              "value": "$376"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "executive_compensation",
          "page": 113,
          "title": "Executive Compensation",
          "data": [
            {
              "key": "Executive Compensation Sections",
              "value": "The sections included in the Proxy Statement that discuss executive compensation."
            },
            {
              "key": "Proxy Statement Date",
              "value": "2023 Annual Meeting of Stockholders"
            },
            {
              "key": "Regulatory Reference",
              "value": "Regulation 14A"
            },
            {
              "key": "Omission Reason",
              "value": "Under General Instruction G(3) to Form 10-K"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 114,
          "title": "Exhibit Index",
          "data": [
            {
              "key": "Exhibit Number",
              "value": "3.1"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "3.2"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "4.1"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Description of Verrica Pharmaceuticals Inc. Common Stock (incorporated herein by reference to Exhibit 4.1 to the Registrant's Annual Report on Form 10-K (File No. 001-38529), filed with the Securities and Exchange Commission on March 13, 2020)."
            },
            {
              "key": "Exhibit Number",
              "value": "0.1"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Amended and Restated Investors' Rights Agreement by and among the Registrant and certain of its stockholders, dated February 20, 2018 (incorporated herein by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "0.2+"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "2013 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "0.3+"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Form of Stock Option Grant Notice and Stock Option Agreement under 2013 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "0.4+"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "2018 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to Amendment No. | to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on June 5, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "0.5+"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Form of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice, and Restricted Stock Unit Award Agreement under 2018 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to Amendment No. | to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on June 5, 2018)"
            },
            {
              "key": "Exhibit Number",
              "value": "0.6+"
            },
            {
              "key": "Exhibits Description of Exhibit",
              "value": "Form of Indemnification Agreement with Executive Officers and Directors (incorporated herein by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1 (File No. 333-225104), filed with the Securities and Exchange Commission on May 22, 2018)"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Services Agreement with PBM Capital Group, LLC",
          "data": [
            {
              "key": "Contract Date",
              "value": "December 2, 2015"
            },
            {
              "key": "Amendment Date",
              "value": "March 29, 2018"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.12 to the Registrant’s Registration Statement on Form S-1 filed with the SEC on May 22, 2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Supply Agreement with Funing County Development Brucea Javanica Professional Cooperatives",
          "data": [
            {
              "key": "Contract Date",
              "value": "July 16, 2018"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2018"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Second Amendment to Services Agreement with PBM Capital Group, LLC",
          "data": [
            {
              "key": "Contract Date",
              "value": "January 1, 2019"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 7, 2019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Lease Agreement with 44 West Gay LLC",
          "data": [
            {
              "key": "Contract Date",
              "value": "July 1, 2019"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Employment Agreement with P. Terence Kohler",
          "data": [
            {
              "key": "Contract Date",
              "value": "July 16, 2021"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 11, 2021"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Third Amendment to Services Agreement with PBM Capital Group, LLC",
          "data": [
            {
              "key": "Contract Date",
              "value": "October 1, 2019"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on November 6, 2019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Amended and Restated Employment Agreement with Ted White",
          "data": [
            {
              "key": "Contract Date",
              "value": "January 10, 2020"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 13, 2020"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "Amended and Restated Employment Agreement with Joe Bonaccorso",
          "data": [
            {
              "key": "Contract Date",
              "value": "January 10, 2020"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 13, 2020"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 115,
          "title": "First Amendment to Lease Agreement with 44 West Gay LLC",
          "data": [
            {
              "key": "Contract Date",
              "value": "March 12, 2020"
            },
            {
              "key": "Reference",
              "value": "Exhibit 10.5 to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2020"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 117,
          "title": "Management Contracts and Compensatory Plans",
          "data": [
            {
              "key": "Description",
              "value": "Indicates management contract or compensatory plan."
            },
            {
              "key": "Confidential Treatment",
              "value": "Confidential treatment has been granted with respect to portions of this exhibit."
            },
            {
              "key": "Regulatory Compliance",
              "value": "Certain portions omitted pursuant to Item 601(b)(10) of Regulation S-K."
            },
            {
              "key": "Certifications",
              "value": "These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "executive_compensation",
          "page": 120,
          "title": "CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002",
          "data": [
            {
              "key": "Executive Name",
              "value": "Ted White"
            },
            {
              "key": "Position",
              "value": "President and Chief Executive Officer (Principal Executive Officer)"
            },
            {
              "key": "Certification Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Report Period End",
              "value": "December 31, 2022"
            },
            {
              "key": "Key Certifications",
              "value": "Reviewed Annual Report, Financial Condition Fairly Presented, Responsibility for Internal Controls"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_rnd_investment_numbers": {
      "value": false,
      "elements": []
    },
    "has_new_product_launches": {
      "value": true,
      "elements": [
        {
          "type": "product_launch",
          "page": 5,
          "title": "Product Pipeline Overview",
          "data": [
            {
              "key": "Product Candidates",
              "value": "VP-102, VP-315, VP-103"
            },
            {
              "key": "Lead Product Candidate",
              "value": "VP-102"
            },
            {
              "key": "Indication",
              "value": "Molluscum contagiosum, external genital warts, common warts"
            },
            {
              "key": "Market Potential",
              "value": "Over $1 billion"
            },
            {
              "key": "FDA Approval Status",
              "value": "None for these diseases"
            },
            {
              "key": "Current Competitors",
              "value": "Compounded cantharidin, cryotherapy, curettage, laser surgery"
            },
            {
              "key": "GMP-Controlled Formulation",
              "value": "Yes"
            },
            {
              "key": "Cantharidin Purity",
              "value": "Greater than 99%"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 6,
          "title": "Product Launch Update for VP-102",
          "data": [
            {
              "key": "Product Name",
              "value": "VP-102"
            },
            {
              "key": "Indication",
              "value": "Treatment of molluscum"
            },
            {
              "key": "NDA Submission Date",
              "value": "September 2019"
            },
            {
              "key": "FDA PDUFA Goal Date",
              "value": "July 13, 2020"
            },
            {
              "key": "CRL Issuance Date",
              "value": "July 2020"
            },
            {
              "key": "Resubmission Date",
              "value": "December 2020"
            },
            {
              "key": "Current NDA Status",
              "value": "Accepted for filing"
            },
            {
              "key": "Latest PDUFA Goal Date",
              "value": "July 23, 2023"
            },
            {
              "key": "Phase 2 Trial for EGW",
              "value": "Initiated in June 2019"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 7,
          "title": "VP-102 - Treatment of Common Warts",
          "data": [
            {
              "key": "Developed Product",
              "value": "VP-102"
            },
            {
              "key": "Indication",
              "value": "Treatment of common warts"
            },
            {
              "key": "Market Size",
              "value": "Over $1 billion"
            },
            {
              "key": "U.S. Patient Visits Annually",
              "value": "2 million"
            },
            {
              "key": "Pediatric Patients Percentage",
              "value": "50%"
            },
            {
              "key": "European and Asian Patient Opportunity",
              "value": "At least as large as in the U.S."
            },
            {
              "key": "Current Treatments",
              "value": "None FDA-approved"
            },
            {
              "key": "Clinical Trial Phase",
              "value": "Completed Phase 2 open label trial"
            },
            {
              "key": "Trial Name",
              "value": "COVE-1"
            },
            {
              "key": "Date of Positive Results Announcement",
              "value": "June 2019"
            },
            {
              "key": "FDA Feedback Status",
              "value": "Evaluating additional Phase 2 trial"
            },
            {
              "key": "Upcoming Trial Parts",
              "value": "Initiating second quarter 2023 for Part 2, second half 2023 for Part 3"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Collaboration and License Agreement Summary",
          "data": [
            {
              "key": "Product Candidates",
              "value": "VP-102, VP-103"
            },
            {
              "key": "Collaboration Partner",
              "value": "Torii Pharmaceutical Co., Ltd."
            },
            {
              "key": "Date of Agreement",
              "value": "March 17, 2021"
            },
            {
              "key": "Payments Received",
              "value": "$0.5 million (Dec 2020), $11.5 million (Apr 2021)"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Indication",
              "value": "Molluscum Contagiosum"
            },
            {
              "key": "Status",
              "value": "Extended through NDA"
            },
            {
              "key": "Milestone",
              "value": "PDUFA Goal Date: July 23, 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Indication",
              "value": "External Genital Warts"
            },
            {
              "key": "Status",
              "value": "Phase 2"
            },
            {
              "key": "Milestone",
              "value": "Initiate Phase 3 in 2H 2024"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Indication",
              "value": "Common Warts"
            },
            {
              "key": "Status",
              "value": "Phase 2"
            },
            {
              "key": "Milestone",
              "value": "Evaluate potential second Phase 2 trial"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Indication",
              "value": "Basal Cell Carcinoma"
            },
            {
              "key": "Status",
              "value": "Phase 2"
            },
            {
              "key": "Milestone",
              "value": "Expect to initiate Part 2 of 3 Part Phase 2 in Q2 2023"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 8,
          "title": "Clinical Development Pipeline",
          "data": [
            {
              "key": "Indication",
              "value": "Plantar Warts"
            },
            {
              "key": "Status",
              "value": "Phase 2"
            },
            {
              "key": "Milestone",
              "value": "Initiate Phase 2 trial"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 9,
          "title": "VP-102 for the Treatment of Molluscum",
          "data": [
            {
              "key": "Description",
              "value": "VP-102 is a proprietary drug-device combination of a novel 0.7% w/v topical solution of cantharidin administered through a single-use precision applicator."
            },
            {
              "key": "Potential",
              "value": "First FDA-approved treatment for molluscum."
            },
            {
              "key": "Address Shortcomings",
              "value": "Addresses pain, discomfort, scarring, and lack of effectiveness associated with current therapies."
            },
            {
              "key": "Formulation Advantages",
              "value": "GMP-controlled formulation of cantharidin, >99% pure API, precise application."
            },
            {
              "key": "Stability Feature",
              "value": "Sealed glass ampule providing long-term room temperature stability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Clinical Development Overview for VP-102",
          "data": [
            {
              "key": "Trial and Status",
              "value": "Phase 3 Clinical Trials (CAMP-1 and CAMP-2) (n=266 and 262, respectively) Top-line results reported in January 2019"
            },
            {
              "key": "Formulation and Application Method",
              "value": "VP-102"
            },
            {
              "key": "Trial Design",
              "value": "Randomized, double-blinded, multicenter, placebo-controlled Safety and efficacy evaluated every 21 days for up to 4 applications"
            },
            {
              "key": "Trial Objectives",
              "value": "To evaluate the efficacy of dermal application of VP-102 relative to placebo for complete clearance at Day 84 To assess the safety and tolerability of VP-102"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Clinical Development Overview for VP-102",
          "data": [
            {
              "key": "Trial and Status",
              "value": "Phase 2 Innovate Trial (n=32) Results reported in September 2018"
            },
            {
              "key": "Formulation and Application Method",
              "value": "VP-102"
            },
            {
              "key": "Trial Design",
              "value": "Open-label, single- center 24-hour treatment Blood draws in subjects with more than 21 lesions for evaluating PK Safety and efficacy evaluated every 21 days for up to four applications Impact of quality of life assessed via the"
            },
            {
              "key": "Trial Objectives",
              "value": "To determine any possible systemic exposure from a single 24-hour application of VP-102 To confirm safety and efficacy with applicator To assess impact on quality of life"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 10,
          "title": "Clinical Development Overview for VP-102",
          "data": [
            {
              "key": "Trial and Status",
              "value": "Phase 2 Investigator Sponsored Pilot Trial (n=30) Completed in September 2017"
            },
            {
              "key": "Formulation and Application Method",
              "value": "Our proprietary formulation of cantharidin used in VP-102, applied with the wooden stick part of a cotton-tipped swab"
            },
            {
              "key": "Trial Design",
              "value": "Open-label, single- center Six hour and 24- hour treatment cohorts Safety and efficacy evaluated every 21 days for up to four applications Impact of quality of life assessed via the CDLQI"
            },
            {
              "key": "Trial Objectives",
              "value": "To evaluate safety and efficacy and determine optimal treatment duration To assess impact on quality of life"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 11,
          "title": "Phase 3 Clinical Trials for VP-102",
          "data": [
            {
              "key": "Trial Names",
              "value": "CAMP-1 and CAMP-2"
            },
            {
              "key": "Announcement Date",
              "value": "January 2019"
            },
            {
              "key": "FDA Submission Date",
              "value": "September 2019"
            },
            {
              "key": "NDA Acceptance Date",
              "value": "November 2019"
            },
            {
              "key": "PDUFA Goal Dates",
              "value": "July 13, 2020; June 23, 2021; September 23, 2021; May 24, 2022"
            },
            {
              "key": "Total Subjects Enrolled",
              "value": "528"
            },
            {
              "key": "Treatment Frequency",
              "value": "Once every 21 days for up to four applications"
            },
            {
              "key": "Complete Clearance at Day 84",
              "value": "46% for CAMP-1 and 54% for CAMP-2"
            },
            {
              "key": "Placebo Clearance at Day 84",
              "value": "18% for CAMP-1 and 13% for CAMP-2"
            },
            {
              "key": "Mean Reduction of Molluscum Lesions",
              "value": "69% (CAMP-1) and 83% (CAMP-2)"
            },
            {
              "key": "Key Side Effects",
              "value": "Application site reactions"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 12,
          "title": "VP-102 Product Development Updates",
          "data": [
            {
              "key": "FDA Communication",
              "value": "The FDA indicated that the NDA resubmission for VP-102 could not accept Sterling as the primary manufacturer if it was on OAI status."
            },
            {
              "key": "New Manufacturer",
              "value": "Piramal Pharma Solutions was selected as the new CMO partner."
            },
            {
              "key": "NDA Resubmission Date",
              "value": "January 23, 2023"
            },
            {
              "key": "FDA Acceptance Date",
              "value": "February 27, 2023"
            },
            {
              "key": "PDUFA Goal Date",
              "value": "July 23, 2023"
            },
            {
              "key": "Treatment Focus",
              "value": "Development of VP-102 for the treatment of External Genital Warts (EGW)."
            },
            {
              "key": "Trial Start Date",
              "value": "June 2019"
            },
            {
              "key": "Phase 2 Trial Results Announcement",
              "value": "November 2020"
            },
            {
              "key": "Efficacy Observation",
              "value": "Statistically significant complete clearance of EGW observed."
            },
            {
              "key": "Safety Profile",
              "value": "Both treatment groups presented comparable and favorable safety profiles."
            },
            {
              "key": "Conclusion",
              "value": "The conduct of a larger placebo-controlled Phase 3 study is warranted."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 15,
          "title": "Supply Agreement and Commercialization Plans",
          "data": [
            {
              "key": "Supply Agreement",
              "value": "Entered into a Supply Agreement with Funing County Development Brucea Javanica Professional Cooperatives on July 16, 2018."
            },
            {
              "key": "Supplier Exclusivity",
              "value": "Supplier will not supply cantharidin to any other customer in North America."
            },
            {
              "key": "Inventory",
              "value": "Held approximately 120,000 finished drug product applicators as of January 31, 2023."
            },
            {
              "key": "Commercial Product",
              "value": "Intended to commercialize VP-102 in the United States."
            },
            {
              "key": "Sales Strategy",
              "value": "Building a specialized sales organization focused on pediatric dermatologists."
            },
            {
              "key": "International Agreement",
              "value": "Entered into the Torii Agreement for commercialization of product candidates in Japan."
            },
            {
              "key": "Market Research Results",
              "value": "87% of surveyed physicians would use VP-102 if reimbursed."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 16,
          "title": "Product Competition and Intellectual Property",
          "data": [
            {
              "key": "Focus of Dermatologists",
              "value": "Safety of pharmaceutical products and preference for topical treatments to limit systemic side effects."
            },
            {
              "key": "Competitive Landscape",
              "value": "Competition from various sources including major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies."
            },
            {
              "key": "VP-102 Competition",
              "value": "Competing with existing treatments such as topical products, cryotherapy, and laser surgery."
            },
            {
              "key": "Regulatory Details",
              "value": "Under Section 503A of the FDCA, compounded products similar to VP-102 would face restrictions on compounding."
            },
            {
              "key": "FDA Processing of Compounded Products",
              "value": "Outsourcing facilities can't compound products without significant clinical difference post approval of VP-102."
            },
            {
              "key": "Current Market for Warts Treatments",
              "value": "No FDA-approved prescription therapies for certain wart treatments, with competition from OTC products."
            },
            {
              "key": "Intellectual Property Protection",
              "value": "Ability to maintain proprietary protection is crucial for commercial success."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 19,
          "title": "Torii Collaboration and License Agreement",
          "data": [
            {
              "key": "Date Entered",
              "value": "August 2020"
            },
            {
              "key": "Product Candidates",
              "value": "VP-102"
            },
            {
              "key": "Option Fee",
              "value": "$0.5 million"
            },
            {
              "key": "Transition to Torii Agreement",
              "value": "March 17, 2021"
            },
            {
              "key": "Development Rights",
              "value": "Exclusive license for product candidates in Japan"
            },
            {
              "key": "Obligations of Torii",
              "value": "Responsible for all development activities and costs for regulatory approval"
            },
            {
              "key": "Milestone Payment",
              "value": "$8.0 million upon first patient dosing"
            },
            {
              "key": "Additional Payments",
              "value": "Up to $50.0 million contingent on milestones"
            },
            {
              "key": "Termination Terms",
              "value": "Either party can terminate for uncured breach or insolvency."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 21,
          "title": "Clinical Trials and IND Requirements",
          "data": [
            {
              "key": "Overview",
              "value": "Combination pharmaceutical and device product review by FDA's Center for Drug Evaluation and Research and Center for Devices and Radiological Health."
            },
            {
              "key": "Required Discussions",
              "value": "The applicant must discuss premarket and post-marketing regulatory requirements with the FDA."
            },
            {
              "key": "Preclinical Studies",
              "value": "Includes laboratory evaluations, toxicity assessments, and animal studies."
            },
            {
              "key": "IND Submission",
              "value": "An IND sponsor must submit results of nonclinical tests and manufacturing information as part of the IND."
            },
            {
              "key": "Clinical Trials",
              "value": "Involve administration of the investigational drug to human subjects under qualified supervision."
            },
            {
              "key": "Phase 1",
              "value": "Drug introduced into healthy subjects, tested for safety and initial effectiveness."
            },
            {
              "key": "Phase 2",
              "value": "Administered to a limited patient population to evaluate safety and efficacy."
            },
            {
              "key": "Phase 3",
              "value": "Expanded patient population for controlled trials to evaluate safety, efficacy, and establish risk-benefit profile."
            },
            {
              "key": "Phase 4 Trials",
              "value": "Conducted post-approval for additional information about the drug."
            },
            {
              "key": "Reporting",
              "value": "Progress reports on clinical trials must be submitted to the FDA annually."
            },
            {
              "key": "Termination of Trials",
              "value": "Trials can be suspended or terminated on various grounds, including health risks."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 34,
          "title": "Product Development and Profitability Challenges",
          "data": [
            {
              "key": "Significant Expenses",
              "value": "Expect to incur significant expenses and operating losses over the next several years."
            },
            {
              "key": "Clinical Trials Support",
              "value": "Will incur additional expenses to continue clinical trials for VP-315, VP-102, and VP-103."
            },
            {
              "key": "Regulatory Approvals",
              "value": "Pursue regulatory approvals for multiple product candidates."
            },
            {
              "key": "Commercialization Plans",
              "value": "Establish infrastructure and scale manufacturing for commercializing approved products."
            },
            {
              "key": "Intellectual Property",
              "value": "Maintain and expand intellectual property portfolio."
            },
            {
              "key": "Personnel Hiring",
              "value": "Hire additional personnel for clinical, manufacturing, and scientific roles."
            },
            {
              "key": "Profitability Risks",
              "value": "Facing multiple risks and uncertainties in product development, profitability is not guaranteed."
            },
            {
              "key": "Market Dependence",
              "value": "Revenue will depend on market size, pricing, coverage, and competition."
            },
            {
              "key": "Regulatory Studies",
              "value": "Potentially required to perform additional studies which could increase expenses."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 35,
          "title": "Financial Condition and Product Launch Plans",
          "data": [
            {
              "key": "Funding Necessity",
              "value": "Substantial additional funding needed to meet financial obligations and pursue business objectives including launching VP-102 for molluscum contagiosum."
            },
            {
              "key": "Product Candidates",
              "value": "VP-102 for molluscum contagiosum, VP-102 for external genital warts, VP-102 for common warts, VP-315 for dermatological oncology, VP-103 for plantar warts."
            },
            {
              "key": "Current Cash",
              "value": "Cash and cash equivalents as of December 31, 2022: $34.3 million."
            },
            {
              "key": "Expected Proceeds",
              "value": "February 2023 offering expected proceeds: $30.1 million."
            },
            {
              "key": "Future Capital Requirements",
              "value": "Dependent on costs/timing of commercialization activities, development program results, and regulatory reviews."
            },
            {
              "key": "Risks of Commercialization",
              "value": "If unable to obtain sufficient funding, may need to liquidate assets and investors may lose investments."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "product_launch",
          "page": 42,
          "title": "Risks and Considerations for Product Development",
          "data": [
            {
              "key": "Regulatory Approval Risks",
              "value": "Failure to obtain or maintain regulatory approval or clearance for the device component of VP-102 may delay market entry."
            },
            {
              "key": "Development Costs",
              "value": "Delays or failures in studies may increase development costs."
            },
            {
              "key": "Manufacturing Changes",
              "value": "Changes in manufacturing methods may lead to additional costs or delays."
            },
            {
              "key": "Pipeline Expansion Strategy",
              "value": "Strategies to expand product pipeline include developing VP-102 and acquiring new candidates."
            },
            {
              "key": "Clinical Trial Risks",
              "value": "Alterations in product formulation may require additional testing and could jeopardize clinical trial outcomes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 43,
          "title": "Product Development and Regulatory Approval Risks",
          "data": [
            {
              "key": "Product Candidates",
              "value": "VP-102, VP-315, VP-103"
            },
            {
              "key": "Indications",
              "value": "Molluscum, Basal Cell Carcinoma"
            },
            {
              "key": "Issues",
              "value": "Regulatory Approval Process, Resource Allocation"
            },
            {
              "key": "Status",
              "value": "No Regulatory Approval Obtained for VP-102"
            },
            {
              "key": "Risks",
              "value": "Potential Failure to Achieve Commercialization, Long FDA Approval Times"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 45,
          "title": "Market strategy and commercialization of VP-102",
          "data": [
            {
              "key": "Key factors for commercial success",
              "value": "Convenience, administration ease, patient willingness, physician prescribing willingness, sales force effectiveness, marketing strength, distribution support, reimbursement availability, side effects prevalence."
            },
            {
              "key": "Risks in commercialization",
              "value": "Failure of healthcare professionals or patients to perceive benefits of VP-102 vs. alternatives; lack of established sales/marketing infrastructure."
            },
            {
              "key": "Future expectations",
              "value": "Building a focused sales and marketing infrastructure upon potential approval."
            },
            {
              "key": "Challenges",
              "value": "Recruitment and training costs, potential delays in product launch, market competition risks."
            },
            {
              "key": "Partnership risks",
              "value": "Reliance on third parties for sales and marketing may lead to lower revenue and profitability."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 46,
          "title": "Market Competition and Product Development",
          "data": [
            {
              "key": "competition_sources",
              "value": "Major pharmaceutical companies, specialty pharmaceutical companies, compounding facilities, academic institutions, governmental agencies, public and private research institutions."
            },
            {
              "key": "product_candidates",
              "value": "Several product candidates in earlier stages for molluscum contagiosum and common warts."
            },
            {
              "key": "NDA_submission",
              "value": "Novan submitted NDA to FDA for VP-102."
            },
            {
              "key": "alternative_therapies",
              "value": "Curettage and cryotherapy."
            },
            {
              "key": "FDA_compounding_rules",
              "value": "Defines compounded products in relation to commercially available drugs."
            },
            {
              "key": "clinical_differences",
              "value": "Determined by prescribing practitioners."
            },
            {
              "key": "bulk_drug_substances",
              "value": "Cantharidin nominated for bulk drug substances."
            },
            {
              "key": "FDA_guidance",
              "value": "Criteria for clinical need for compounding with bulk drug substance."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 49,
          "title": "Market and Product Liability Considerations for VP-102",
          "data": [
            {
              "key": "Product Candidate",
              "value": "VP-102"
            },
            {
              "key": "Lead Indications",
              "value": "Molluscum, external genital warts, common warts"
            },
            {
              "key": "Market Risks",
              "value": "Market for VP-102 may not be as large as expected"
            },
            {
              "key": "Approval Conditions",
              "value": "Approval does not guarantee market acceptance"
            },
            {
              "key": "Insurance Coverage",
              "value": "Current coverage is $10 million, may not be adequate"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 54,
          "title": "Collaboration Challenges and Product Development",
          "data": [
            {
              "key": "collaborator_delays",
              "value": "Collaborators may delay clinical trials and provide insufficient funding."
            },
            {
              "key": "collaborator_competition",
              "value": "Collaborators could develop competing products."
            },
            {
              "key": "resource_commitment",
              "value": "Collaborators may not devote sufficient resources for commercialization."
            },
            {
              "key": "disagreements",
              "value": "Disagreements might cause delays or termination of development."
            },
            {
              "key": "intellectual_property_risks",
              "value": "Collaborators may infringe or improperly maintain IP rights."
            },
            {
              "key": "termination_of_collaboration",
              "value": "Collaborations may be terminated for convenience, necessitating additional capital."
            },
            {
              "key": "capital_requirements",
              "value": "Product development will require substantial additional capital."
            },
            {
              "key": "exclusive_license",
              "value": "Entered into an exclusive license with Torii for product candidates."
            },
            {
              "key": "competition_for_collaborators",
              "value": "Face significant competition in seeking collaborators."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "product_launch",
          "page": 79,
          "title": "Management’s Discussion and Analysis of Financial Condition and Results of Operations",
          "data": [
            {
              "key": "Product Candidates",
              "value": "VP-102, VP-315, VP-103"
            },
            {
              "key": "Focus",
              "value": "Dermatology therapeutics for skin diseases requiring medical intervention."
            },
            {
              "key": "Lead Product Candidate",
              "value": "VP-102"
            },
            {
              "key": "Clinical Trials",
              "value": "Phase 3 CAMP-1 and CAMP-2 trials for VP-102"
            },
            {
              "key": "FDA Submission Date",
              "value": "September 2019"
            },
            {
              "key": "FDA PDUFA Goal Date",
              "value": "July 13, 2020"
            },
            {
              "key": "Resubmission of NDA",
              "value": "December 2020"
            },
            {
              "key": "Next PDUFA Goal Date",
              "value": "June 23, 2021"
            },
            {
              "key": "FDA CRL Issuance Date",
              "value": "September 17, 2021"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_capital_expenditures": {
      "value": true,
      "elements": [
        {
          "type": "capital_expenditure",
          "page": 88,
          "title": "Investing Activities and Funding Requirements",
          "data": [
            {
              "key": "Net cash provided by investing activities (2022)",
              "value": "$59.0 million"
            },
            {
              "key": "Purchases of marketable securities (2022)",
              "value": "$4.5 million"
            },
            {
              "key": "Purchases of property and equipment (2022)",
              "value": "$0.3 million"
            },
            {
              "key": "Net cash used in investing activities (2021)",
              "value": "$68.9 million"
            },
            {
              "key": "Purchases of property and equipment (2021)",
              "value": "$0.9 million"
            },
            {
              "key": "Voluntary repayment of outstanding debt (2022)",
              "value": "$43.8 million"
            },
            {
              "key": "Net proceeds from issuance of common stock (2022)",
              "value": "$26.9 million"
            },
            {
              "key": "Funding requirements due to increased expenses",
              "value": "Expected increase in research and development costs, commercialization expenses, and operating costs"
            },
            {
              "key": "Existing cash and cash equivalents as of December 31, 2022",
              "value": "Sufficient to support operations into first quarter of 2024"
            },
            {
              "key": "Estimated recent capital raising efforts (February 2023)",
              "value": "$30.1 million from offering of common stock and pre-funded warrants"
            },
            {
              "key": "Factors affecting future capital requirements",
              "value": "Regulatory review costs, clinical trial costs, patent application costs, compliance costs, product acquisition costs, COVID-19 impact, manufacturing arrangement costs, sales and marketing costs."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "capital_expenditure",
          "page": 99,
          "title": "Asset Depreciation Schedule",
          "data": [
            {
              "key": "Machinery and equipment",
              "value": "3-5 years"
            },
            {
              "key": "Office furniture and fixtures and equipment",
              "value": "3 years"
            },
            {
              "key": "Leasehold improvements",
              "value": "Lease Term"
            },
            {
              "key": "Automobiles",
              "value": "3 years"
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_financial_performance_indicators": {
      "value": true,
      "elements": [
        {
          "type": "financial_performance",
          "page": 84,
          "title": "Financial Uncertainties in Product Development",
          "data": [
            {
              "key": "uncertainties_in_product_development",
              "value": "The successful development of product candidates is highly uncertain due to numerous risks and uncertainties associated with clinical trials."
            },
            {
              "key": "general_and_administrative_expenses",
              "value": "General and administrative expenses will increase as headcount is expected to grow to support business expansion."
            },
            {
              "key": "net_operating_loss_carryforwards",
              "value": "As of December 31, 2022, federal and state net operating loss carryforwards were approximately $118.1 million and $120.7 million, respectively."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 85,
          "title": "Financial Performance Summary",
          "data": [
            {
              "key": "Collaboration revenue 2022",
              "value": "9032"
            },
            {
              "key": "Collaboration revenue 2021",
              "value": "12000"
            },
            {
              "key": "Change in Collaboration revenue",
              "value": "-2968"
            },
            {
              "key": "Research and development 2022",
              "value": "12198"
            },
            {
              "key": "Research and development 2021",
              "value": "15929"
            },
            {
              "key": "Change in Research and development",
              "value": "-3731"
            },
            {
              "key": "General and administrative 2022",
              "value": "17405"
            },
            {
              "key": "General and administrative 2021",
              "value": "26979"
            },
            {
              "key": "Change in General and administrative",
              "value": "-9574"
            },
            {
              "key": "Cost of collaboration revenue 2022",
              "value": "725"
            },
            {
              "key": "Cost of collaboration revenue 2021",
              "value": "0"
            },
            {
              "key": "Change in Cost of collaboration revenue",
              "value": "725"
            },
            {
              "key": "Total expenses 2022",
              "value": "30328"
            },
            {
              "key": "Total expenses 2021",
              "value": "42908"
            },
            {
              "key": "Change in Total expenses",
              "value": "-12580"
            },
            {
              "key": "Loss from operations 2022",
              "value": "-21296"
            },
            {
              "key": "Loss from operations 2021",
              "value": "-30908"
            },
            {
              "key": "Change in Loss from operations",
              "value": "9612"
            },
            {
              "key": "Interest income 2022",
              "value": "476"
            },
            {
              "key": "Interest income 2021",
              "value": "123"
            },
            {
              "key": "Change in Interest income",
              "value": "353"
            },
            {
              "key": "Interest expense 2022",
              "value": "-2172"
            },
            {
              "key": "Interest expense 2021",
              "value": "-4295"
            },
            {
              "key": "Change in Interest expense",
              "value": "2123"
            },
            {
              "key": "Loss on extinguishment of debt 2022",
              "value": "-1437"
            },
            {
              "key": "Loss on extinguishment of debt 2021",
              "value": "0"
            },
            {
              "key": "Change in Loss on extinguishment of debt",
              "value": "-1437"
            },
            {
              "key": "Other expense 2022",
              "value": "-68"
            },
            {
              "key": "Other expense 2021",
              "value": "0"
            },
            {
              "key": "Change in Other expense",
              "value": "-8"
            },
            {
              "key": "Total other expense, net 2022",
              "value": "-3191"
            },
            {
              "key": "Total other expense, net 2021",
              "value": "-4172"
            },
            {
              "key": "Change in Total other expense, net",
              "value": "981"
            },
            {
              "key": "Net loss 2022",
              "value": "-24487"
            },
            {
              "key": "Net loss 2021",
              "value": "-35080"
            },
            {
              "key": "Change in Net loss",
              "value": "10593"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 86,
          "title": "General and Administrative Expenses Summary",
          "data": [
            {
              "key": "General_Administrative_Expenses_2022",
              "value": "$17.4 million"
            },
            {
              "key": "General_Administrative_Expenses_2021",
              "value": "$27.0 million"
            },
            {
              "key": "Decrease_in_Expenses",
              "value": "$9.6 million"
            },
            {
              "key": "Cost_of_Collaboration_Revenue_2022",
              "value": "$0.7 million"
            },
            {
              "key": "Cost_of_Collaboration_Revenue_2021",
              "value": "$0"
            },
            {
              "key": "Interest_Income_Increase",
              "value": "$0.4 million"
            },
            {
              "key": "Interest_Expense_Decrease",
              "value": "$2.1 million"
            },
            {
              "key": "Loss_on_Extinguishment_of_Debt",
              "value": "$1.4 million"
            },
            {
              "key": "Total_Net_Proceeds_from_Stock_Offerings",
              "value": "$30.1 million"
            },
            {
              "key": "Cash_and_Cash_Equivalent_as_of_Dec_31_2022",
              "value": "$34.3 million"
            },
            {
              "key": "Operating_Lease_Obligations",
              "value": "$1.8 million through Sept 1, 2027"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 87,
          "title": "Cash Flow Summary",
          "data": [
            {
              "key": "Net cash used in operating activities 2022",
              "value": "-18650"
            },
            {
              "key": "Net cash used in operating activities 2021",
              "value": "-27582"
            },
            {
              "key": "Net cash provided by (used in) investing activities 2022",
              "value": "54041"
            },
            {
              "key": "Net cash provided by (used in) investing activities 2021",
              "value": "-998"
            },
            {
              "key": "Net cash (used in) provided by financing activities 2022",
              "value": "-16870"
            },
            {
              "key": "Net cash (used in) provided by financing activities 2021",
              "value": "33646"
            },
            {
              "key": "Net increase in cash and cash equivalents 2022",
              "value": "18521"
            },
            {
              "key": "Net increase in cash and cash equivalents 2021",
              "value": "5066"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 91,
          "title": "Financial Statements Index",
          "data": [
            {
              "key": "Financial Statement",
              "value": "Balance Sheets as of December 31, 2022 and 2021"
            },
            {
              "key": "Page Number",
              "value": "92"
            },
            {
              "key": "Financial Statement",
              "value": "Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Page Number",
              "value": "93"
            },
            {
              "key": "Financial Statement",
              "value": "Statements of Stockholders' Equity for the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Page Number",
              "value": "94"
            },
            {
              "key": "Financial Statement",
              "value": "Statements of Cash Flows for the years ended December 31, 2022 and 2021"
            },
            {
              "key": "Page Number",
              "value": "95"
            },
            {
              "key": "Financial Statement",
              "value": "Notes to Financial Statements"
            },
            {
              "key": "Page Number",
              "value": "96"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 92,
          "title": "Report of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company Name",
              "value": "Verrica Pharmaceuticals Inc."
            },
            {
              "key": "Opinion on Financial Statements",
              "value": "The financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021."
            },
            {
              "key": "Going Concern",
              "value": "Substantial operating losses since inception raise substantial doubt about the Company’s ability to continue as a going concern."
            },
            {
              "key": "Audit Responsibility",
              "value": "The financial statements are the responsibility of the Company’s management."
            },
            {
              "key": "Auditor Firm",
              "value": "KPMG LLP"
            },
            {
              "key": "Audit Opinion Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Audit Period",
              "value": "Years ended December 31, 2022 and 2021."
            },
            {
              "key": "Independence Statement",
              "value": "The firm is registered with the PCAOB and required to be independent."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 93,
          "title": "Balance Sheet Assets and Liabilities",
          "data": [
            {
              "key": "Current assets: Cash and cash equivalents",
              "value": "2022: 34,273, 2021: 15,752"
            },
            {
              "key": "Current assets: Marketable securities",
              "value": "2022: 0, 2021: 54,602"
            },
            {
              "key": "Current assets: Total current assets",
              "value": "2022: 39,115, 2021: 74,328"
            },
            {
              "key": "Assets: Total assets",
              "value": "2022: 44,721, 2021: 80,125"
            },
            {
              "key": "Liabilities: Total current liabilities",
              "value": "2022: 3,459, 2021: 46,055"
            },
            {
              "key": "Liabilities: Total liabilities",
              "value": "2022: 4,688, 2021: 47,520"
            },
            {
              "key": "Stockholders' equity: Additional paid-in capital",
              "value": "2022: 203,482, 2021: 171,597"
            },
            {
              "key": "Stockholders' equity: Total stockholders' equity",
              "value": "2022: 40,033, 2021: 32,605"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 94,
          "title": "Financial Results Comparison 2022 vs 2021",
          "data": [
            {
              "key": "Collaboration revenue",
              "value": "$9,032"
            },
            {
              "key": "Research and development",
              "value": "$12,198"
            },
            {
              "key": "General and administrative",
              "value": "$17,405"
            },
            {
              "key": "Cost of collaboration revenue",
              "value": "$725"
            },
            {
              "key": "Total expenses",
              "value": "$30,328"
            },
            {
              "key": "Loss from operations",
              "value": "-$21,296"
            },
            {
              "key": "Interest income",
              "value": "$476"
            },
            {
              "key": "Interest expense",
              "value": "-$2,172"
            },
            {
              "key": "Loss on extinguishment of debt",
              "value": "-$1,437"
            },
            {
              "key": "Total other expense, net",
              "value": "-$3,191"
            },
            {
              "key": "Net loss",
              "value": "-$24,487"
            },
            {
              "key": "Net loss per share, basic and diluted",
              "value": "-$0.72"
            },
            {
              "key": "Weighted-average common shares outstanding",
              "value": "34,163,437"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 95,
          "title": "Stockholders' Equity Statement",
          "data": [
            {
              "key": "Balance as of December 31, 2020",
              "value": "Shares Issued: 25,546,257, Amount: 3.3, Additional Paid-In Capital: 136,868, Accumulated Deficit: (103,886), Stockholders' Equity: 32,986"
            },
            {
              "key": "Stock-based compensation",
              "value": "Shares Issued: —, Additional Paid-In Capital: 6,053, Stockholders Equity: 6,053"
            },
            {
              "key": "Issuance of common stock, net of issuance costs",
              "value": "Shares Issued: 2,033,899, Stockholders Equity: 28,118"
            },
            {
              "key": "Exercise of stock options",
              "value": "Shares Issued: 44,041, Additional Paid-In Capital: 558, Stockholders Equity: 558"
            },
            {
              "key": "Net loss",
              "value": "Accumulated Deficit: (35,080), Stockholders Equity: (35,080)"
            },
            {
              "key": "Balance as of December 31, 2021",
              "value": "Shares Issued: 27,624,197, Amount: 3, Additional Paid-In Capital: 171,597, Accumulated Deficit: (138,966), Stockholders' Equity: 32,605"
            },
            {
              "key": "Stock-based compensation",
              "value": "Shares Issued: —, Additional Paid-In Capital: 4,985, Stockholders Equity: 4,985"
            },
            {
              "key": "Issuance of common stock, net of issuance costs",
              "value": "Shares Issued: 13,575,000, Amount: 1, Additional Paid-In Capital: 26,900, Stockholders Equity: 26,901"
            },
            {
              "key": "Net loss",
              "value": "Accumulated Deficit: (24,487), Stockholders Equity: (24,487)"
            },
            {
              "key": "Unrealized gain on marketable securities",
              "value": "Other Comprehensive Income: 29, Stockholders Equity: 29"
            },
            {
              "key": "Balance as of December 31, 2022",
              "value": "Shares Issued: 41,199,197, Amount: 4, Additional Paid-In Capital: 203,482, Accumulated Deficit: (163,453), Stockholders' Equity: 40,033"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 96,
          "title": "Cash Flow Statement",
          "data": [
            {
              "key": "Net loss",
              "value": "-24487"
            },
            {
              "key": "Stock-based compensation",
              "value": "4985"
            },
            {
              "key": "Amortization of premiums on marketable securities",
              "value": "108"
            },
            {
              "key": "Depreciation expense",
              "value": "454"
            },
            {
              "key": "Net cash used in operating activities",
              "value": "-18650"
            },
            {
              "key": "Net cash provided by (used in) investing activities",
              "value": "54041"
            },
            {
              "key": "Cash and cash equivalents at the end of the year",
              "value": "34273"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 97,
          "title": "Liquidity and Capital Resources",
          "data": [
            {
              "key": "accumulated_deficit",
              "value": "$163.5 million"
            },
            {
              "key": "upfront_payment_received_from_Torii",
              "value": "$11.5 million"
            },
            {
              "key": "milestone_payment_received_from_Torii",
              "value": "$8.0 million"
            },
            {
              "key": "net_proceeds_follow_on_PUBLIC_offering",
              "value": "$28.1 million"
            },
            {
              "key": "net_proceeds_July_2022_offering",
              "value": "$26.9 million"
            },
            {
              "key": "net_proceeds_February_2023_offering",
              "value": "$30.1 million"
            },
            {
              "key": "cash_and_cash_equivalents",
              "value": "$34.3 million"
            },
            {
              "key": "total_debt_repaid",
              "value": "$35.0 million"
            },
            {
              "key": "additional_funding_needed",
              "value": "Substantial"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 98,
          "title": "Assessment of COVID-19 Impact on Financial Performance",
          "data": [
            {
              "key": "Functional Currency",
              "value": "U.S. dollar"
            },
            {
              "key": "COVID-19 Impact",
              "value": "Management believes results were not significantly impacted by COVID-19."
            },
            {
              "key": "Estimates and Assumptions",
              "value": "Management estimates based on current facts and historical experience."
            },
            {
              "key": "Operating Segment",
              "value": "The Company operates in one segment."
            },
            {
              "key": "Cash Equivalents",
              "value": "Highly liquid investments with original maturities of 90 days or less."
            },
            {
              "key": "Marketable Securities",
              "value": "Classified as available-for-sale pursuant to ASC 320."
            },
            {
              "key": "Unrealized Gains/Losses",
              "value": "Recorded as accumulated other comprehensive gain or loss."
            },
            {
              "key": "Credit Risk",
              "value": "Not exposed to significant credit risk due to financial strength of institutions."
            },
            {
              "key": "Off-Balance Sheet Risk",
              "value": "No financial instruments with off-balance sheet risk of loss."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Marketable Securities Portfolio Summary",
          "data": [
            {
              "key": "S. treasury securities amortized cost",
              "value": "15,272"
            },
            {
              "key": "S. treasury securities unrealized losses",
              "value": "-15"
            },
            {
              "key": "S. treasury securities fair value",
              "value": "15,257"
            },
            {
              "key": "Commercial paper amortized cost",
              "value": "28,980"
            },
            {
              "key": "Commercial paper unrealized losses",
              "value": "0"
            },
            {
              "key": "Commercial paper fair value",
              "value": "28,980"
            },
            {
              "key": "Asset-backed securities amortized cost",
              "value": "10,379"
            },
            {
              "key": "Asset-backed securities unrealized losses",
              "value": "-14"
            },
            {
              "key": "Asset-backed securities fair value",
              "value": "10,365"
            },
            {
              "key": "Total amortized cost",
              "value": "54,631"
            },
            {
              "key": "Total unrealized losses",
              "value": "-29"
            },
            {
              "key": "Total fair value",
              "value": "54,602"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 103,
          "title": "Securities by Fair Value Level",
          "data": [
            {
              "key": "S. treasury securities fair value",
              "value": "15,257"
            },
            {
              "key": "Commercial paper fair value",
              "value": "28,980"
            },
            {
              "key": "Asset-backed securities fair value",
              "value": "10,365"
            },
            {
              "key": "Total fair value",
              "value": "54,602"
            },
            {
              "key": "Level 1 total",
              "value": "15,257"
            },
            {
              "key": "Level 2 total",
              "value": "39,345"
            },
            {
              "key": "Level 3 total",
              "value": "0"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 104,
          "title": "Machinery and equipment breakdown for 2021-2022",
          "data": [
            {
              "key": "Total property and equipment, net 2022",
              "value": "3,887"
            },
            {
              "key": "Total property and equipment, net 2021",
              "value": "3,894"
            },
            {
              "key": "Accumulated depreciation 2022",
              "value": "(699)"
            },
            {
              "key": "Accumulated depreciation 2021",
              "value": "(254)"
            },
            {
              "key": "Depreciation expense for 2022",
              "value": "454,000"
            },
            {
              "key": "Depreciation expense for 2021",
              "value": "244,000"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 109,
          "title": "Debt Details and Income Taxes",
          "data": [
            {
              "key": "Loan Details",
              "value": "The Company entered into the Mezzanine Loan Agreement and Senior Loan Agreement on March 10, 2020, borrowing $35 million initially and later an additional $5 million. The total repayment was $43.8 million including principal and fees."
            },
            {
              "key": "Loss on Debt Extinguishment",
              "value": "For the year ended December 31, 2022, the Company recognized a $1.4 million loss on debt extinguishment."
            },
            {
              "key": "Interest Expense",
              "value": "Interest expenses for 2022 and 2021 were $2.2 million and $4.3 million, respectively."
            },
            {
              "key": "Income Tax Provision",
              "value": "No provision for income taxes due to operating losses; total tax computation differences for 2022 and 2021 shown."
            },
            {
              "key": "Significant Changes",
              "value": "Change in tax rate effect was $4,637 for 2022, and a change in valuation allowance decreased from $9,551 in 2021."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "financial_performance",
          "page": 119,
          "title": "Consent of Independent Registered Public Accounting Firm",
          "data": [
            {
              "key": "Company",
              "value": "Verrica Pharmaceuticals Inc."
            },
            {
              "key": "Report Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Accounting Firm",
              "value": "KPMG LLP"
            },
            {
              "key": "Location",
              "value": "Philadelphia, Pennsylvania"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "financial_performance",
          "page": 121,
          "title": "Certification of Principal Executive Officer",
          "data": [
            {
              "key": "Certifying Officer",
              "value": "P. Terence Kohler, Jr."
            },
            {
              "key": "Document Type",
              "value": "Annual Report on Form 10-K"
            },
            {
              "key": "Year Ended",
              "value": "December 31, 2022"
            },
            {
              "key": "Certification Date",
              "value": "March 6, 2023"
            },
            {
              "key": "Responsibilities",
              "value": "Reviewed the report; ensured no misleading statements; presented financial condition fairly."
            },
            {
              "key": "Internal Control Assessment",
              "value": "Evaluated effectiveness of disclosure controls and procedures."
            },
            {
              "key": "Changes in Internal Controls",
              "value": "Disclosed changes affecting internal control over financial reporting."
            },
            {
              "key": "Deficiencies Disclosed",
              "value": "All significant deficiencies and material weaknesses disclosed."
            },
            {
              "key": "Fraud Disclosure",
              "value": "Disclosed any fraud involving management or significant employees."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_dividend_policy_changes": {
      "value": true,
      "elements": [
        {
          "type": "dividend_policy",
          "page": 78,
          "title": "Dividend Policy",
          "data": [
            {
              "key": "Dividend Declaration",
              "value": "We have never declared or paid, and do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock."
            },
            {
              "key": "Intention for Funds",
              "value": "We intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business."
            },
            {
              "key": "Loan Agreements Restriction",
              "value": "We are restricted from paying dividends or making other distributions or payments on our capital stock, subject to limited exceptions."
            },
            {
              "key": "Future Determination Factors",
              "value": "Future determinations will depend on results of operations, financial condition, capital requirements, contractual restrictions, business prospects, and other factors deemed relevant by the board."
            },
            {
              "key": "Stockholder Information",
              "value": "As of March 1, 2023, we had 41,852,053 shares of common stock outstanding held by 20 holders of record."
            },
            {
              "key": "Stock Listing",
              "value": "Our common stock is listed on the Nasdaq Global Select Market under the symbol 'VRCA'."
            },
            {
              "key": "Additional Notes",
              "value": "The actual number of stockholders is greater than record holders and includes beneficial owners whose shares are held in street name."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_share_buyback_plans": {
      "value": false,
      "elements": []
    },
    "has_capital_structure_changes": {
      "value": false,
      "elements": []
    },
    "mentions_new_risk_factors": {
      "value": true,
      "elements": [
        {
          "type": "risk_factor",
          "page": 32,
          "title": "ITEM 1A. RISK FACTORS",
          "data": [
            {
              "key": "Significant losses",
              "value": "The company has incurred significant losses since inception and expects to incur losses over the next several years."
            },
            {
              "key": "Need for additional funding",
              "value": "Substantial additional funding will be needed to meet financial obligations and pursue business objectives."
            },
            {
              "key": "Limited operating history",
              "value": "The company has a limited operating history and no history of commercializing products."
            },
            {
              "key": "Regulatory approval uncertainty",
              "value": "The timing for VP-102 approval is uncertain due to a CRL from the FDA."
            },
            {
              "key": "Competition",
              "value": "Substantial competition exists from compounded products that may affect VP-102's commercial opportunity."
            },
            {
              "key": "Reimbursement challenges",
              "value": "Success depends on coverage and reimbursement for VP-102 treatments."
            },
            {
              "key": "Market size",
              "value": "The market for VP-102 and other candidates may be smaller than expected."
            },
            {
              "key": "Dependency on third parties",
              "value": "The company relies on third parties for supplies, impacting operations if issues arise."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 38,
          "title": "Risks Related to Product Candidates and Clinical Development",
          "data": [
            {
              "key": "Regulatory Approval Challenges",
              "value": "Product candidates may never obtain regulatory approval despite substantial time and resources."
            },
            {
              "key": "Clinical Development Uncertainty",
              "value": "Clinical development is lengthy, expensive, and outcomes are uncertain, leading to potential delays."
            },
            {
              "key": "Failure of Clinical Trials",
              "value": "Failure can occur at any stage of clinical testing, and interim results may not predict final outcomes."
            },
            {
              "key": "Cost of Trials",
              "value": "Preclinical and clinical testing can incur additional costs and delays."
            },
            {
              "key": "Market Authorization Risk",
              "value": "There is no assurance that clinical trials will demonstrate efficacy for marketing approval."
            },
            {
              "key": "Patient Enrollment Issues",
              "value": "Enrollment might be slower or more difficult than anticipated, with potential for higher dropout rates."
            },
            {
              "key": "Side Effects and Suspension Risk",
              "value": "Product candidates may have unexpected side effects that can cause trials to be suspended or terminated."
            },
            {
              "key": "Contractor Compliance Issues",
              "value": "Third-party contractors may fail to comply with regulatory requirements or contractual obligations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 39,
          "title": "Clinical Trial Risks and Delays",
          "data": [
            {
              "key": "Regulatory Compliance Risks",
              "value": "Regulators or institutional review boards may require the suspension or termination of clinical development due to noncompliance with regulatory requirements."
            },
            {
              "key": "Cost of Trials",
              "value": "The cost of clinical trials may be greater than anticipated."
            },
            {
              "key": "Material Quality and Supply Risks",
              "value": "The supply or quality of product candidates or other materials may be insufficient or inadequate."
            },
            {
              "key": "Delays Due to Suspension",
              "value": "Delays may occur if a trial is suspended or terminated for a variety of reasons."
            },
            {
              "key": "Adverse Events",
              "value": "Unforeseen safety issues or adverse side effects could result in trial delays."
            },
            {
              "key": "Funding Issues",
              "value": "A lack of adequate funding may prevent the continuation of clinical trials."
            },
            {
              "key": "Impact of Delays",
              "value": "Delays in completion or termination of clinical trials could harm commercial prospects and delay revenue generation."
            },
            {
              "key": "Regulatory Approval Denials",
              "value": "Delays or additional trials may lead to the denial of regulatory approval."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 41,
          "title": "Risks Related to Product Development and Regulatory Approval",
          "data": [
            {
              "key": "Potential Impact of Preliminary Data",
              "value": "Differences may result in final data being materially different from preliminary data, affecting business prospects."
            },
            {
              "key": "Clinical Trials Risks",
              "value": "Clinical trials may fail to demonstrate safety and efficacy, leading to potential abandonment or limitation of product development."
            },
            {
              "key": "Regulatory Approval Delays",
              "value": "Regulatory approvals may be delayed or denied due to unforeseen safety information or adverse side effects."
            },
            {
              "key": "Consequences of Side Effects",
              "value": "Identifiable side effects may lead to withdrawal of approvals or additional warnings, affecting market acceptance."
            },
            {
              "key": "Regulatory Risks for VP-102",
              "value": "VP-102 being a drug-device combination may face increased regulatory complexities and delays."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 52,
          "title": "Risk of Manufacturing and Supply Chain Disruptions",
          "data": [
            {
              "key": "Issue",
              "value": "Risk of inability to scale cantharidin synthesis process"
            },
            {
              "key": "Impact",
              "value": "Potential reliance on naturally sourced cantharidin impacting operations"
            },
            {
              "key": "Third_party_relations",
              "value": "Dependence on third-party manufacturers for production of VP-102"
            },
            {
              "key": "Regulatory_risks",
              "value": "Need for contract manufacturer compliance with FDA regulations"
            },
            {
              "key": "Approval_issues",
              "value": "Past CRL received from FDA regarding deficiencies in contractor facilities"
            },
            {
              "key": "Consequences",
              "value": "Potential delays in commercialization and clinical trials due to manufacturing issues"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 55,
          "title": "Risks Related to Our Intellectual Property",
          "data": [
            {
              "key": "Risk of collaboration complications",
              "value": "Collaborations are complex and may not be negotiated on acceptable terms."
            },
            {
              "key": "Financial risk from insufficient funds",
              "value": "If unable to fund development and commercialization, may not bring products to market."
            },
            {
              "key": "Intellectual property protection risks",
              "value": "Inability to obtain or protect intellectual property rights could hinder competition."
            },
            {
              "key": "Potential prior art affecting patents",
              "value": "Prior art may invalidate patents or prevent issuance from pending applications."
            },
            {
              "key": "Dependence on third-party patents",
              "value": "Future in-licenses may limit ability to control patent prosecution."
            },
            {
              "key": "Confidentiality risks",
              "value": "Trade secrets may not be adequately protected, allowing competitors to replicate advantages."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 57,
          "title": "Risks Related to Patent Protection and Intellectual Property",
          "data": [
            {
              "key": "Patent Issues",
              "value": "Changes in patent laws or interpretations may diminish the value of intellectual property."
            },
            {
              "key": "Leahy-Smith Act Impact",
              "value": "The implementation of the Leahy-Smith America Invents Act has introduced uncertainties surrounding patent applications."
            },
            {
              "key": "Jurisprudential Concerns",
              "value": "U.S. Supreme Court rulings may weaken patent rights."
            },
            {
              "key": "Foreign Patent Law Variance",
              "value": "Patent protection may vary by country, impacting our ability to defend intellectual property."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 61,
          "title": "Risks associated with trade secrets and intellectual property rights",
          "data": [
            {
              "key": "Risk of unauthorized disclosure or use of trade secrets",
              "value": "Despite confidentiality agreements, there is an increased risk of competitors learning our trade secrets."
            },
            {
              "key": "Effect of unauthorized disclosure on business",
              "value": "Unauthorized use of proprietary technology can adversely affect business operations."
            },
            {
              "key": "Monitoring difficulties",
              "value": "Monitoring unauthorized uses and disclosures is challenging."
            },
            {
              "key": "Limits of intellectual property rights",
              "value": "Intellectual property rights may not sufficiently protect competitive advantage."
            },
            {
              "key": "Potential liabilities from disclosed information",
              "value": "Liabilities may arise from unauthorized disclosure of licensed confidential information."
            },
            {
              "key": "Challenges in enforcing trade secret protections",
              "value": "Litigation to enforce trade secret protections is expensive and outcomes are unpredictable."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 68,
          "title": "Regulatory and Compliance Risks",
          "data": [
            {
              "key": "FCPA Compliance Risks",
              "value": "Giving, or authorizing others to give, anything of value to non-U.S. government officials to influence action."
            },
            {
              "key": "Record Keeping Requirements",
              "value": "Public companies must keep accurate records reflecting transactions and maintain internal controls."
            },
            {
              "key": "Employee Compliance Risks",
              "value": "Uncertainty in compliance with laws by employees, agents, and partners."
            },
            {
              "key": "Potential Violations Consequences",
              "value": "Violations could lead to fines, criminal sanctions, and operational restrictions."
            },
            {
              "key": "Impact on Competition",
              "value": "Government regulations may impair ability to compete in international markets."
            },
            {
              "key": "Export Control Regulations",
              "value": "Exports must comply with U.S. and international laws, with potential penalties for violations."
            },
            {
              "key": "Delays from Regulatory Changes",
              "value": "Changes in regulations could delay product introduction and sales."
            },
            {
              "key": "Key Personnel Dependence",
              "value": "Success depends on retaining key executives and recruiting qualified personnel."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 70,
          "title": "Risks Related to Ownership of Our Common Stock and Our Status as a Public Company",
          "data": [
            {
              "key": "risk_description",
              "value": "The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses."
            },
            {
              "key": "influencing_factors",
              "value": "The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility."
            },
            {
              "key": "specific_risks",
              "value": "Factors influencing stock price volatility include clinical trial results, regulatory delays, adverse regulatory decisions, financial estimates changes, market trends, investor perception, recruitment or departure of key personnel, and significant lawsuits."
            },
            {
              "key": "mentions_lawsuits",
              "value": "Stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of market volatility."
            },
            {
              "key": "potential_impact",
              "value": "Such litigation could cause us to incur substantial costs and divert management’s attention."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 71,
          "title": "Market Risks Related to Sales of Common Stock and Corporate Governance Provisions",
          "data": [
            {
              "key": "Risk Description",
              "value": "Sales of a substantial number of shares of our common stock could cause the market price of our common stock to drop significantly."
            },
            {
              "key": "Key Factors",
              "value": "Outstanding shares available for sale in public market, restrictions of Rule 144, corporate charter provisions."
            },
            {
              "key": "Anti-Takeover Provisions",
              "value": "Certificate of incorporation and bylaws may make it difficult for a third party to acquire control."
            },
            {
              "key": "Ownership Concentration",
              "value": "Executive officers and directors own a majority of shares, influencing corporate decisions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 74,
          "title": "Exclusive Forum Provisions and Risk Management",
          "data": [
            {
              "key": "Exclusive Forum Provision",
              "value": "Court of Chancery of Delaware and federal district courts of the USA are exclusive forums for disputes."
            },
            {
              "key": "Potential Limitation on Stockholders",
              "value": "Limited ability for stockholders to obtain favorable judicial forum for disputes."
            },
            {
              "key": "Risks of Cyber-Attacks",
              "value": "Business may suffer due to cyber system failures, litigation, or disruptions."
            },
            {
              "key": "Types of Cyber Threats",
              "value": "Include computer viruses, malware, natural disasters, terrorism, cyber-intrusions."
            },
            {
              "key": "Consequences of Cyber Threats",
              "value": "Disruption of operations, reputational harm, loss of profits."
            },
            {
              "key": "Specific Cyber Risks Mentioned",
              "value": "Social-engineering attacks, ransomware attacks, denial-of-service attacks."
            },
            {
              "key": "Impact of Cyber-Attacks on Clinical Trials",
              "value": "Loss of trial data can delay regulatory approvals and increase costs."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 75,
          "title": "Risk Factors Related to Data Security and Economic Conditions",
          "data": [
            {
              "key": "Data Security Risks",
              "value": "Disruption or security incident could lead to loss or damage to data or applications."
            },
            {
              "key": "Legal Liabilities",
              "value": "Risk of litigation and reputational harm due to data privacy and security obligations."
            },
            {
              "key": "Insurance Coverage",
              "value": "Uncertainty regarding adequacy of insurance coverage for privacy and security practices."
            },
            {
              "key": "Global Economic Conditions",
              "value": "Inflation and economic uncertainty could limit business growth and affect operating results."
            },
            {
              "key": "COVID-19 Impact",
              "value": "Continued disruptions in workforce, supply chain, and regulatory approvals due to pandemic."
            },
            {
              "key": "Supply Chain Constraints",
              "value": "Possible delays in obtaining raw materials and capacity constraints at suppliers."
            },
            {
              "key": "Stock Market Volatility",
              "value": "Risks related to the sustainability of an active trading market for common stock."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "risk_factor",
          "page": 90,
          "title": "Quantitative and Qualitative Disclosures About Market Risk",
          "data": [
            {
              "key": "Market Risk Exposure",
              "value": "Interest rate sensitivity primarily affected by changes in U.S. interest rates."
            },
            {
              "key": "Types of Investments",
              "value": "Investments include U.S. Treasury securities, asset-backed securities, and commercial paper."
            },
            {
              "key": "Impact of Interest Rates",
              "value": "Marketable securities subject to interest rate risk; value may fall if rates increase."
            },
            {
              "key": "Short-term Nature",
              "value": "Investments have a short-term nature and low-risk profile."
            },
            {
              "key": "Effect of Interest Rate Change",
              "value": "An immediate 100 basis point change in rates is not expected to have a material effect."
            },
            {
              "key": "Holding Securities",
              "value": "Marketable securities can be held until maturity."
            },
            {
              "key": "Foreign Currency Exposure",
              "value": "Exposed to fluctuations in foreign currency exchange rates due to vendor contracts."
            },
            {
              "key": "Hedging Currency Risk",
              "value": "Currently, there is no hedging for foreign currency exchange rate risk."
            },
            {
              "key": "Liabilities in Foreign Currencies",
              "value": "As of December 31, 2022, minimal or no liabilities were in foreign currencies."
            },
            {
              "key": "Inflation Impact",
              "value": "Inflation increases costs of labor and clinical trials but had no material effect during 2022."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_guidance_updates": {
      "value": true,
      "elements": [
        {
          "type": "guidance_update",
          "page": 2,
          "title": "Forward-Looking Statements Summary",
          "data": [
            {
              "key": "statement_type",
              "value": "forward-looking"
            },
            {
              "key": "risks",
              "value": "substantial risks and uncertainties"
            },
            {
              "key": "identified_sections",
              "value": "Part I, Item 1; Part I, Item 1A; Part II, Item 7"
            },
            {
              "key": "terms_used",
              "value": "may, might, will, could, would, should, expect, intend, plan, objective, anticipate, believe, estimate, predict, project, potential, continue, ongoing"
            },
            {
              "key": "caution",
              "value": "statements based on a combination of facts and expectations about the future"
            },
            {
              "key": "discussed_factors",
              "value": "development and commercialization of product candidates, timing of clinical trials, regulatory approvals, commercialization capabilities, third-party reimbursement, intellectual property, recruiting and retaining personnel, impact of laws, global economic uncertainty"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 3,
          "title": "Forward-looking Statements Disclaimer",
          "data": [
            {
              "key": "Statement Type",
              "value": "Forward-looking Statements"
            },
            {
              "key": "Obligation to Update",
              "value": "No obligation to publicly update any forward-looking statements unless required by law."
            },
            {
              "key": "Company References",
              "value": "References to 'the Company', 'we', 'our', etc."
            },
            {
              "key": "Trademark Information",
              "value": "Includes trademarks of Verrica Pharmaceuticals Inc. and other properties."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Table of Contents",
          "data": [
            {
              "key": "Item 1A.",
              "value": "Risk Factors"
            },
            {
              "key": "Item 1B.",
              "value": "Unresolved Staff Comments"
            },
            {
              "key": "Item 2.",
              "value": "Properties"
            },
            {
              "key": "Item 3.",
              "value": "Legal Proceedings"
            },
            {
              "key": "Item 4.",
              "value": "Mine Safety Disclosures"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Part II",
          "data": [
            {
              "key": "Item 6.",
              "value": "Reserved"
            },
            {
              "key": "Item 7.",
              "value": "Management's Discussion and Analysis of Financial Condition and Results of Operations"
            },
            {
              "key": "Item 7A.",
              "value": "Quantitative and Qualitative Disclosures About Market Risk"
            },
            {
              "key": "Item 8.",
              "value": "Financial Statements and Supplementary Data"
            },
            {
              "key": "Item 9.",
              "value": "Changes in and Disagreements with Accountants on Accounting and Financial Disclosure"
            },
            {
              "key": "Item 9A.",
              "value": "Controls and Procedures"
            },
            {
              "key": "Item 9B.",
              "value": "Other Information"
            },
            {
              "key": "Item 9C",
              "value": "Disclosure Regarding Foreign Jurisdictions that Prevent Inspections"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 4,
          "title": "Part IV",
          "data": [
            {
              "key": "Item 16.",
              "value": "Signatures"
            },
            {
              "key": "Part IV.",
              "value": "Form 10-K Summary"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 22,
          "title": "Marketing Approval Process for NDA",
          "data": [
            {
              "key": "Clinical Trials Overview",
              "value": "Concurrent with clinical trials, companies complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the product."
            },
            {
              "key": "NDA Submission",
              "value": "Assuming successful completion of required clinical testing, results are submitted to the FDA as part of an NDA requesting approval."
            },
            {
              "key": "PDUFA Guidelines",
              "value": "Under the Prescription Drug User Fee Act, the FDA aims for a ten-month review period from the date of filing of a standard NDA."
            },
            {
              "key": "Pediatric Research Equity Act",
              "value": "Certain NDAs must contain data for pediatric subpopulations regarding safety and effectiveness."
            },
            {
              "key": "Risk Evaluation and Mitigation Strategy",
              "value": "FDA may require submission of a REMS plan to ensure benefits outweigh risks."
            },
            {
              "key": "FDA Review Process",
              "value": "FDA conducts a preliminary review of NDAs within the first 60 days after submission."
            },
            {
              "key": "Inspection Requirements",
              "value": "FDA inspects facilities and clinical trial sites to ensure compliance with safety and quality standards."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 31,
          "title": "Available Information",
          "data": [
            {
              "key": "Website",
              "value": "www.verrica.com"
            },
            {
              "key": "SEC Website",
              "value": "www.sec.gov"
            },
            {
              "key": "Types of Reports Available",
              "value": "Annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 36,
          "title": "Funding and Capital Raising Risks",
          "data": [
            {
              "key": "Risks of Additional Capital Raising",
              "value": "Dependent on market conditions and may lead to dilution of stockholders' ownership."
            },
            {
              "key": "Current Funding Situation",
              "value": "No committed external source of funds."
            },
            {
              "key": "Debt Financing Implications",
              "value": "May impose restrictions on operations, including dividend declarations."
            },
            {
              "key": "Product Development Challenges",
              "value": "Current lack of approved products and history of commercialization may impact future viability."
            },
            {
              "key": "Regulatory Approval Status",
              "value": "NDA submitted for VP-102, previously received a CRL from FDA due to manufacturing issues."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 47,
          "title": "Guidance for Industry on NCE Exclusivity for VP-102",
          "data": [
            {
              "key": "NCE Exclusivity",
              "value": "Eligible for NCE exclusivity if approved."
            },
            {
              "key": "Pediatric Exclusivity",
              "value": "May qualify for pediatric exclusivity with FDA request."
            },
            {
              "key": "Competition Risks",
              "value": "Risk of competition if compounding of cantharidin products is allowed."
            },
            {
              "key": "Regulatory Approval Timeline",
              "value": "Competitors may obtain FDA approval faster."
            },
            {
              "key": "Market Entry Barriers",
              "value": "Potential delays if competitors secure FDA approval first."
            },
            {
              "key": "Resources of Competitors",
              "value": "Competitors may have greater financial resources and expertise."
            },
            {
              "key": "Mergers and Acquisitions Impact",
              "value": "Concentration of resources among fewer competitors through M&As."
            },
            {
              "key": "Pediatric Studies Requirement",
              "value": "Must fulfill FDA request for pediatric studies to extend exclusivity."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 72,
          "title": "Reporting Exemptions and Internal Control",
          "data": [
            {
              "key": "Emerging Growth Company Status",
              "value": "The company identifies itself as an 'emerging growth company' as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act)."
            },
            {
              "key": "Exemptions from Reporting Requirements",
              "value": "The company intends to take advantage of exemptions under JOBS Act which includes providing only two years of audited financial statements and reduced disclosure obligations regarding executive compensation."
            },
            {
              "key": "Potential Impact on Stock Attractiveness",
              "value": "The reliance on exemptions may render the company's stock less attractive to some investors leading to a less active trading market."
            },
            {
              "key": "Internal Controls",
              "value": "The company is subject to the Sarbanes-Oxley Act and has to maintain internal controls which they evaluate for effectiveness."
            },
            {
              "key": "Emerging Growth Company Expiration",
              "value": "The status as an emerging growth company will end on December 31, 2023."
            },
            {
              "key": "Limitations of Control Systems",
              "value": "No control system can provide absolute assurance that misstatements due to error or fraud won't occur."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 73,
          "title": "Potential Regulatory and Compliance Risks",
          "data": [
            {
              "key": "Section 404 Sarbanes-Oxley Act compliance risks",
              "value": "Failure to comply may affect financial statements accuracy and result in decline of stock price and investigations."
            },
            {
              "key": "Net operating loss carryforwards",
              "value": "As of December 31, 2022, federal NOL carryforwards of approximately $118.1 million and state of $120.7 million."
            },
            {
              "key": "Limitation on NOL usage due to ownership change",
              "value": "If a corporation undergoes a greater than 50% change in equity ownership, usage of NOLs may be limited."
            },
            {
              "key": "Dividend policy",
              "value": "No anticipated cash dividends; focus on retaining earnings for business growth."
            },
            {
              "key": "Increased costs of being a public company",
              "value": "Legal, accounting and compliance costs affecting financial results."
            },
            {
              "key": "Risks from compliance failures",
              "value": "Failures may lead to regulatory actions, higher insurance costs, and difficulties in attracting qualified board members."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 81,
          "title": "Financial Performance and Guidance Update",
          "data": [
            {
              "key": "collaboration_revenue_billed",
              "value": "0.9 million"
            },
            {
              "key": "collaboration_revenue_unbilled",
              "value": "0.1 million"
            },
            {
              "key": "total_net_proceeds_IPO",
              "value": "78.4 million"
            },
            {
              "key": "total_net_proceeds_follow_on_March_2021",
              "value": "28.1 million"
            },
            {
              "key": "total_net_proceeds_follow_on_July_2022",
              "value": "26.9 million"
            },
            {
              "key": "total_net_proceeds_February_2023",
              "value": "30.1 million"
            },
            {
              "key": "net_loss_2022",
              "value": "24.5 million"
            },
            {
              "key": "net_loss_2021",
              "value": "35.1 million"
            },
            {
              "key": "accumulated_deficit_as_of_2022",
              "value": "163.5 million"
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 83,
          "title": "Emerging Growth Company and Operating Results",
          "data": [
            {
              "key": "JOBS Act",
              "value": "In April 2012, the Jumpstart Our Business Startups Act of 2012 was enacted."
            },
            {
              "key": "Extended Transition Period",
              "value": "An emerging growth company can delay the adoption of certain accounting standards."
            },
            {
              "key": "Adoption Deadline",
              "value": "We will remain an emerging growth company until December 31, 2023."
            },
            {
              "key": "Collaboration Revenue",
              "value": "Collaboration revenue represents revenue from the Torii Agreement."
            },
            {
              "key": "Operating Expenses",
              "value": "Research and development expenses consist of expenses incurred in connection with the discovery and development of our product candidates."
            },
            {
              "key": "R&D Increase Expectation",
              "value": "We expect our research and development expenses to increase over the next several years."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 89,
          "title": "Financial Statements on Going Concern Basis",
          "data": [
            {
              "key": "Going Concern Assumption",
              "value": "The financial statements have been prepared on a going concern basis, contemplating the realization of assets and satisfaction of liabilities in the normal course of business."
            },
            {
              "key": "Uncertainty About Continued Operations",
              "value": "Substantial doubt about the ability to continue as a going concern due to anticipated additional losses until marketing approval of VP-102."
            },
            {
              "key": "Financing Needs",
              "value": "Substantial additional financing needed to fund operations and to develop and commercialize the drug candidate."
            },
            {
              "key": "Capital Raising Impact Factors",
              "value": "Ability to raise additional capital may be adversely impacted by global economic conditions and covid-19 pandemic."
            },
            {
              "key": "Potential Dilution",
              "value": "Raising additional capital through equity or convertible debt may dilute existing stockholders' interests."
            },
            {
              "key": "Debt Financing Limitations",
              "value": "Debt financing may involve agreements that restrict actions such as incurring additional debt, capital expenditures or declaring dividends."
            },
            {
              "key": "Contractual Obligations (Lytix Agreement)",
              "value": "Exclusive license agreement with Lytix for technology to research and commercialize VP-315, with initial and milestone payments outlined."
            },
            {
              "key": "Payment Obligations",
              "value": "Additional payments due upon achievement of operational milestones; royalties based on sales to be shared with Lytix."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 100,
          "title": "Revenue Recognition and Research & Development Costs",
          "data": [
            {
              "key": "revenue_recognition_principles",
              "value": "Identification of the promised goods or services in the contract; determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract."
            },
            {
              "key": "up_front_license_fees",
              "value": "Revenue recognized from nonrefundable, up-front fees allocated to the license when transferred to the licensee."
            },
            {
              "key": "milestone_payments",
              "value": "Evaluates whether each milestone is probable of being achieved to estimate the transaction price."
            },
            {
              "key": "royalties",
              "value": "Revenue recognized at the later of when sales occur or when performance obligation has been satisfied."
            },
            {
              "key": "manufacturing_supply_services",
              "value": "Recognized as collaboration revenue if options do not provide a material right."
            },
            {
              "key": "research_and_development_costs",
              "value": "Consist primarily of clinical trials costs, salaries, payroll taxes, and are expensed as incurred."
            }
          ],
          "currency": "USD"
        },
        {
          "type": "guidance_update",
          "page": 102,
          "title": "Income Taxes",
          "data": [
            {
              "key": "Accounting standard",
              "value": "ASC 740, Income Taxes"
            },
            {
              "key": "Deferred tax assets and liabilities",
              "value": "Recorded for future tax consequences"
            },
            {
              "key": "Valuation allowances",
              "value": "Recognized if deferred tax assets are unlikely to be realized"
            },
            {
              "key": "Uncertain tax positions",
              "value": "Accounted for under ASC 740"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 102,
          "title": "Net Loss Per Share",
          "data": [
            {
              "key": "Computed by",
              "value": "Dividing net loss by weighted average shares"
            },
            {
              "key": "Dilutive effect",
              "value": "Excludes common stock options and unvested shares"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 102,
          "title": "Share-Based Compensation Summary",
          "data": [
            {
              "key": "Category 2022",
              "value": "Shares issuable upon exercise of stock options: 3,932,779"
            },
            {
              "key": "Category 2021",
              "value": "Shares issuable upon exercise of stock options: 3,443,817"
            },
            {
              "key": "Category 2022 Non-vested shares",
              "value": "425,000"
            },
            {
              "key": "Category 2021 Non-vested shares",
              "value": "425,000"
            },
            {
              "key": "Total 2022",
              "value": "4,357,779"
            },
            {
              "key": "Total 2021",
              "value": "3,868,817"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 102,
          "title": "Recently Adopted Accounting Pronouncements",
          "data": [
            {
              "key": "FASB ASU No. 2022-03",
              "value": "Fair Value Measurement of Equity Securities"
            },
            {
              "key": "Effective date",
              "value": "January 1, 2024"
            },
            {
              "key": "Material impact",
              "value": "Not expected"
            },
            {
              "key": "FASB ASU 2016-13",
              "value": "Financial Instruments—Credit Losses"
            },
            {
              "key": "Effective date ASU 2016-13",
              "value": "January 1, 2023"
            },
            {
              "key": "Impact",
              "value": "Not expected to be material"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "guidance_update",
          "page": 112,
          "title": "Changes in and Disagreements with Accountants on Accounting and Financial Disclosure",
          "data": [
            {
              "key": "Disclosure Controls Effectiveness",
              "value": "Effective at the reasonable assurance level as of December 31, 2022"
            },
            {
              "key": "Internal Control Over Financial Reporting",
              "value": "Effective as of December 31, 2022"
            },
            {
              "key": "Attestation Requirement",
              "value": "Not applicable as per Section 404(c) of the Sarbanes Oxley Act due to emerging growth company status"
            },
            {
              "key": "Changes in Internal Control",
              "value": "No changes identified that materially affect internal control over financial reporting."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_regulatory_or_litigation_issues": {
      "value": true,
      "elements": [
        {
          "type": "regulatory_litigation",
          "page": 20,
          "title": "Government Regulation and Product Approval",
          "data": [
            {
              "key": "Regulatory Body",
              "value": "FDA"
            },
            {
              "key": "Regulatory Requirements",
              "value": "FDCA and its implementing regulations"
            },
            {
              "key": "Approval Process Overview",
              "value": "Requires preclinical tests, IND submission, clinical trials, NDA submission, FDA inspections"
            },
            {
              "key": "Potential Consequences of Non-compliance",
              "value": "Refusal to approve, withdrawal of approval, clinical hold, fines"
            },
            {
              "key": "Combination Product Status",
              "value": "VP-102 is a drug device combination product."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 24,
          "title": "FDA Approval and Patent Challenges",
          "data": [
            {
              "key": "Certification Notice",
              "value": "FDA is prohibited from approving the application until the earlier of 30 months from receipt of the paragraph IV certification, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the applicant."
            },
            {
              "key": "Non-Patent Exclusivity Period",
              "value": "Pharmaceutical manufacturers may obtain five years of non-patent exclusivity upon NDA approval of a New Chemical Entity."
            },
            {
              "key": "Pediatric Exclusivity",
              "value": "Exclusivity period may be extended by an additional six months if certain requirements are met for pediatric studies."
            },
            {
              "key": "Post-Approval Requirements",
              "value": "Drugs manufactured under FDA approvals are subject to ongoing regulation, including recordkeeping and reporting."
            },
            {
              "key": "Changes to Approved Product",
              "value": "Any changes to the approved product require further testing and FDA review."
            },
            {
              "key": "cGMP Compliance",
              "value": "Manufacturers must maintain compliance with current Good Manufacturing Practice (cGMP) regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 25,
          "title": "FDA Regulatory Compliance and Enforcement Actions",
          "data": [
            {
              "key": "Approval Withdrawal",
              "value": "The FDA may withdraw approval if regulatory compliance is not maintained."
            },
            {
              "key": "Mandatory Revisions",
              "value": "Mandatory revisions to labeling may be necessary if new safety information is discovered."
            },
            {
              "key": "Potential Enforcement Actions",
              "value": "Restrictions on marketing, product withdrawals, recalls, and potential fines."
            },
            {
              "key": "Promotion Regulations",
              "value": "Promotions must align with approved indications according to the label."
            },
            {
              "key": "Physician Actions",
              "value": "Physicians may prescribe off-label, but manufacturers' communications are restricted."
            },
            {
              "key": "Compounding Regulations",
              "value": "Compounding may be exempt under certain conditions specified in Sections 503A and 503B."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 26,
          "title": "FDA Regulations on Compounding and Outsourcing Facilities",
          "data": [
            {
              "key": "Section 503A",
              "value": "Compounding can only use bulk drug substances on an FDA-approved list."
            },
            {
              "key": "Section 503B",
              "value": "Allows compounding without individual patient prescriptions."
            },
            {
              "key": "Outsourcing Facility Registration",
              "value": "Must register with the FDA and meet conditions for exemption."
            },
            {
              "key": "cGMP Compliance",
              "value": "Drugs must be compounded under cGMP and licensed pharmacist supervision."
            },
            {
              "key": "Reporting Requirements",
              "value": "Outsourcing facilities must report compounded product information."
            },
            {
              "key": "Cantharidin Status",
              "value": "Nominated substance for compounding while FDA evaluates it."
            },
            {
              "key": "2019 FDA Guidance",
              "value": "Addressing clinical need evaluation for compounded drugs."
            },
            {
              "key": "Prohibited Actions",
              "value": "Cannot sell compounded drugs through wholesale distributors."
            },
            {
              "key": "Inspection Frequency",
              "value": "FDA inspections are risk-based."
            },
            {
              "key": "Federal and State Laws",
              "value": "Restricts biopharmaceutical business practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 27,
          "title": "Federal Anti-Kickback Statute Overview",
          "data": [
            {
              "key": "Legal Framework",
              "value": "The federal Anti-Kickback Statute prohibits offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or recommending any reimbursable item or service."
            },
            {
              "key": "Remuneration Definition",
              "value": "Broadly interpreted to include anything of value."
            },
            {
              "key": "Applicability",
              "value": "Applies to pharmaceutical manufacturers and prescribers, purchasers, formulary managers, etc."
            },
            {
              "key": "Exceptions and Safe Harbors",
              "value": "Narrowly drawn, require strict compliance for protection against prosecution."
            },
            {
              "key": "Liability",
              "value": "A person or entity can violate the statute without actual knowledge or specific intent."
            },
            {
              "key": "False Claims Act",
              "value": "Claims resulting from a violation may constitute a false claim for government reimbursement."
            },
            {
              "key": "HIPAA Overview",
              "value": "Prohibits schemes to defraud healthcare benefit programs and mandates protection of health information."
            },
            {
              "key": "HITECH Act",
              "value": "Imposes civil monetary penalties and expands HIPAA applicability to business associates."
            },
            {
              "key": "Physician Payments Sunshine Act",
              "value": "Requires manufacturers to report payments and transfers of value to healthcare professionals."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 28,
          "title": "Regulatory Compliance and Reimbursement Challenges",
          "data": [
            {
              "key": "Key Regulations",
              "value": "State and foreign laws equivalent to federal laws regarding healthcare compliance"
            },
            {
              "key": "Compliance Costs",
              "value": "Substantial costs involved to ensure compliance with healthcare laws"
            },
            {
              "key": "Potential Penalties",
              "value": "Civil, criminal, and administrative penalties for non-compliance"
            },
            {
              "key": "Third-Party Coverage",
              "value": "Coverage and reimbursement depend largely on third-party payors"
            },
            {
              "key": "Challenges in Reimbursement",
              "value": "Difficulty obtaining reimbursement for high-priced drugs administered by physicians"
            },
            {
              "key": "Factors Impacting Reimbursement",
              "value": "Safety, effectiveness, medical necessity, and cost-effectiveness among payors"
            },
            {
              "key": "Variability in Decisions",
              "value": "Coverage decisions vary by each third-party payor."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 29,
          "title": "Impact of Healthcare Reform on Business Performance",
          "data": [
            {
              "key": "Healthcare Reform Impact",
              "value": "Legislative and regulatory changes in healthcare that may delay marketing approval and affect sales of drug candidates."
            },
            {
              "key": "Patient Protection and Affordable Care Act (ACA)",
              "value": "Significantly changes financing of healthcare and impacts pharmaceutical industry."
            },
            {
              "key": "Medicaid Drug Rebate Program",
              "value": "Increased minimum Medicaid rebates and expanded rebate program."
            },
            {
              "key": "Fees on Drug Manufacturers",
              "value": "Established non-deductible fees for manufacturers based on market share."
            },
            {
              "key": "340B Drug Pricing Program",
              "value": "Expanded availability of lower pricing and added new entities."
            },
            {
              "key": "Patient-Centered Outcomes Research Institute",
              "value": "Created to oversee comparative clinical effectiveness research."
            },
            {
              "key": "Impact of American Rescue Plan Act",
              "value": "Eliminates statutory Medicaid drug rebate cap starting January 1, 2024."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 30,
          "title": "Impact of Legislative Changes on Medicare and Pharmaceutical Pricing Practices",
          "data": [
            {
              "key": "Year",
              "value": "2012"
            },
            {
              "key": "Legislative Change",
              "value": "Reduction of Medicare payments to providers"
            },
            {
              "key": "Implications",
              "value": "Adverse effect on financial operations due to funding reductions"
            },
            {
              "key": "Government Scrutiny",
              "value": "Heightened scrutiny of pharmaceutical pricing practices"
            },
            {
              "key": "Executive Orders",
              "value": "Biden administration's executive order on competition in the economy"
            },
            {
              "key": "IRA Provisions",
              "value": "Negotiation of drug prices and penalties for price increases"
            },
            {
              "key": "State Legislation",
              "value": "Increasing control over pharmaceutical pricing and patient reimbursement"
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 40,
          "title": "Clinical Trials and Regulatory Challenges",
          "data": [
            {
              "key": "regulatory_authorities",
              "value": "FDA or similar regulatory authorities outside the United States"
            },
            {
              "key": "enrollment_factors",
              "value": "eligibility criteria, perceived risks and benefits, availability of products and treatments, patient willingness, timely enrollment efforts, physician referral practices, monitoring ability, proximity of clinical trial sites"
            },
            {
              "key": "consequences_of_insufficient_enrollment",
              "value": "significant delays, potential abandonment of clinical trials, increased development costs, decline in company value, limited financing ability"
            },
            {
              "key": "CROs_dependency",
              "value": "reliance on CROs and clinical trial sites for timely conduct of trials"
            },
            {
              "key": "clinical_trials_success",
              "value": "success in early trials may not predict later trial results"
            },
            {
              "key": "design_flaws_impact",
              "value": "design flaws of clinical trials may not be apparent until well advanced"
            },
            {
              "key": "regulatory_delays",
              "value": "data interpretation variability, impacts from regulatory policy changes"
            },
            {
              "key": "interim_results_variability",
              "value": "interim top-line results are subject to change as more data becomes available."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 44,
          "title": "Regulatory Challenges for VP-102",
          "data": [
            {
              "key": "NDA Submission",
              "value": "Resubmitted NDA for VP-102 on January 23, 2023."
            },
            {
              "key": "CRL Received",
              "value": "Received a Complete Response Letter (CRL) from the FDA regarding NDA for VP-102."
            },
            {
              "key": "FDA Interaction",
              "value": "Held a Type A meeting with the FDA on June 27, 2022."
            },
            {
              "key": "New CMO Partner",
              "value": "Selected Piramal Pharma Solutions as new CMO partner in January 2023."
            },
            {
              "key": "FDA Acceptance",
              "value": "FDA accepted NDA resubmission on February 27, 2023."
            },
            {
              "key": "PDUFA Goal Date",
              "value": "Assigned goal date of July 23, 2023 for NDA."
            },
            {
              "key": "Market Acceptance Risks",
              "value": "Market acceptance by physicians and payors is necessary for commercial success."
            },
            {
              "key": "Effect of Delays",
              "value": "Delays in approval or inability to obtain approval will adversely affect operations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 48,
          "title": "Reimbursement Challenges for VP-102",
          "data": [
            {
              "key": "Coverage Importance",
              "value": "The success of VP-102 depends significantly on coverage and adequate reimbursement."
            },
            {
              "key": "Patient Payment Reluctance",
              "value": "Patients may be unwilling to pay out of pocket without coverage."
            },
            {
              "key": "Reimbursement Difficulties",
              "value": "Obtaining coverage may be particularly difficult due to higher associated prices."
            },
            {
              "key": "Third-Party Payors",
              "value": "Decisions of third-party payors affect coverage and reimbursement."
            },
            {
              "key": "Policy Variability",
              "value": "There is no uniform policy among third-party payors, leading to inconsistencies."
            },
            {
              "key": "Medicare Influence",
              "value": "Third-party payors often rely on Medicare when setting their policies."
            },
            {
              "key": "Approval Uncertainty",
              "value": "The approval and adoption of VP-102 can depend on these reimbursement issues."
            },
            {
              "key": "Legislative Changes",
              "value": "Pending healthcare legislation can impact business operations."
            },
            {
              "key": "Impact of MACRA",
              "value": "The Medicare Access and CHIP Reauthorization Act may change payment structures."
            },
            {
              "key": "International Variation",
              "value": "Healthcare reimbursement varies significantly by country."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 50,
          "title": "Regulatory Compliance Risks",
          "data": [
            {
              "key": "Hazardous Materials Compliance Risk",
              "value": "Our business activities involve the use of hazardous materials, requiring compliance with environmental and occupational safety laws. Violations can lead to fines and liabilities."
            },
            {
              "key": "Third-Party Manufacturer Liability",
              "value": "We rely on third-party product manufacturers who also use hazardous materials, which could lead to liabilities from accidents."
            },
            {
              "key": "Insurance Coverage",
              "value": "Current insurance may not cover all pollution conditions or extraordinary events."
            },
            {
              "key": "Changes in Regulations",
              "value": "Future changes in environmental laws could impose costly compliance requirements."
            },
            {
              "key": "Third-Party Clinical Trials Risks",
              "value": "Relying on third parties for clinical trials may lead to delays and inadequate performance."
            },
            {
              "key": "Control Over CROs",
              "value": "We rely on third parties for execution of our preclinical studies and clinical trials, which reduces our control."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 53,
          "title": "Regulatory Compliance Risks",
          "data": [
            {
              "key": "Issue",
              "value": "Third-party manufacturers may not comply with cGMP regulations."
            },
            {
              "key": "Consequences",
              "value": "Sanctions could include clinical holds, fines, license revocation, delays, etc."
            },
            {
              "key": "Concerns",
              "value": "Dependence on third-party manufacturers for product candidates."
            },
            {
              "key": "Manufacturing Challenges",
              "value": "Need to validate automated assembly processes."
            },
            {
              "key": "Collaboration Risks",
              "value": "Dependence on collaborations for product candidate development."
            },
            {
              "key": "Example Agreement",
              "value": "Torii Agreement for exclusive licensing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 56,
          "title": "Concerns About Trade Secrets and Intellectual Property Protection",
          "data": [
            {
              "key": "Main Topic",
              "value": "Intellectual Property Rights and Trade Secrets"
            },
            {
              "key": "Concern",
              "value": "Inability to effectively protect trade secrets and patents."
            },
            {
              "key": "Impact",
              "value": "Potential adverse effect on competitive advantage and business operations."
            },
            {
              "key": "Regulation Mentioned",
              "value": "FDA rules on information disclosure."
            },
            {
              "key": "Geographical Limitation",
              "value": "Limited patent protection across different jurisdictions."
            },
            {
              "key": "Legal System Issues",
              "value": "Difficult enforcement of intellectual property rights in certain countries."
            },
            {
              "key": "Potential Solutions",
              "value": "Efforts to protect intellectual property in significant markets."
            },
            {
              "key": "Risks Associated",
              "value": "Costs associated with enforcement and potential lawsuits."
            },
            {
              "key": "Licensing Laws",
              "value": "Some jurisdictions may impose compulsory licensing."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 58,
          "title": "Patent Protection and Legal Risks",
          "data": [
            {
              "key": "Application Process",
              "value": "Employs reputable law firms and professionals for compliance."
            },
            {
              "key": "Consequences of Non-Compliance",
              "value": "Potential loss of patent rights."
            },
            {
              "key": "Patent Applications",
              "value": "Cover specific formulations and processes."
            },
            {
              "key": "Cantharidin",
              "value": "Not eligible for patent protection."
            },
            {
              "key": "Market Competition",
              "value": "Competitors may develop alternative formulations."
            },
            {
              "key": "Enforcement Challenges",
              "value": "Method of use patents are difficult to enforce."
            },
            {
              "key": "Off-Label Usage",
              "value": "Common practice across medical specialties."
            },
            {
              "key": "Patent Litigation Risks",
              "value": "Could be expensive and unsuccessful."
            },
            {
              "key": "Invalidity Claims",
              "value": "Common in patent litigation."
            },
            {
              "key": "Legal Proceedings",
              "value": "Includes IPR and opposition proceedings."
            },
            {
              "key": "Outcomes",
              "value": "Unpredictable results in legal assertions."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 59,
          "title": "Intellectual Property Litigation Risks",
          "data": [
            {
              "key": "risk_description",
              "value": "The company faces potential invalidation of patents and unenforceability claims which could lead to cessation of relevant technology use or adverse impacts on commercialization."
            },
            {
              "key": "outcomes_of_litigation",
              "value": "Adverse results in litigation could result in losing patent protection, increased litigation costs, and management distractions."
            },
            {
              "key": "third_party_claims",
              "value": "Third parties may initiate legal proceedings alleging patent infringements, posing risks to the company’s product candidates."
            },
            {
              "key": "confidentiality_risks",
              "value": "There is a risk of confidential information being compromised due to the discovery process in litigation."
            },
            {
              "key": "impact_on_stock_price",
              "value": "Negative perceptions from securities analysts or investors due to litigation outcomes could adversely affect stock prices."
            },
            {
              "key": "license_obtaining_risks",
              "value": "If found infringing, obtaining licenses from patent holders may not be feasible or may not come at commercially reasonable terms."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 60,
          "title": "Patent Litigation and Intellectual Property Issues",
          "data": [
            {
              "key": "Main Issue",
              "value": "Potential challenges arising from required licenses and intellectual property rights."
            },
            {
              "key": "Impact of Infringement Claims",
              "value": "Could lead to substantial monetary damages and limit marketing of products."
            },
            {
              "key": "Litigation Costs",
              "value": "Defending against litigation would divert management's attention and incur substantial costs."
            },
            {
              "key": "Risks from Third-Party Claims",
              "value": "Claims of misappropriation could negatively impact operations."
            },
            {
              "key": "Employment Concerns",
              "value": "Former employees may disclose confidential information, leading to disputes."
            },
            {
              "key": "Intellectual Property Assignment",
              "value": "Issues with enforcing agreements for intellectual property ownership."
            },
            {
              "key": "Long-Term Consequences",
              "value": "Unsuccessful defense could result in loss of valuable rights."
            },
            {
              "key": "Collaboration Risks",
              "value": "Sharing trade secrets with third-party manufacturers increases risk of misappropriation."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 62,
          "title": "Risks Related to Legal and Regulatory Compliance Matters",
          "data": [
            {
              "key": "Regulatory Risks",
              "value": "Potential non-compliance with federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws."
            },
            {
              "key": "Anti-Kickback Statute Impact",
              "value": "Prohibition against remuneration for services linked to federal healthcare programs."
            },
            {
              "key": "False Claims Act Penalties",
              "value": "Claims made under false pretenses facing substantial penalties."
            },
            {
              "key": "HIPAA Violations",
              "value": "Criminal statutes prohibiting fraud in healthcare benefits."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 63,
          "title": "Overview of U.S. and Foreign Data Privacy Regulations",
          "data": [
            {
              "key": "Privacy Compliance Issues",
              "value": "Privacy, security and transmission of individually identifiable health information without appropriate authorization."
            },
            {
              "key": "HITECH Act",
              "value": "Created new tiers of civil monetary penalties and amended HIPAA for applicability to business associates."
            },
            {
              "key": "Federal Transparency Laws",
              "value": "Includes the Physician Payments Sunshine Act requiring manufacturers to report payments to physicians."
            },
            {
              "key": "State Law Requirements",
              "value": "State laws requiring manufacturers to report information on payments to healthcare providers."
            },
            {
              "key": "U.S. Data Privacy Regulations",
              "value": "Includes CCPA which provides new rights for consumers regarding personal data."
            },
            {
              "key": "California Privacy Rights Act",
              "value": "Effective January 1, 2023, expands CCPA and establishes new enforcement agency."
            },
            {
              "key": "Foreign Data Privacy Regulations",
              "value": "GDPR imposes fines for non-compliance and has stringent operational requirements."
            },
            {
              "key": "Data Localization Laws",
              "value": "Restrict the transfer of personal data outside the EEA."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 64,
          "title": "Regulatory and Legal Compliance Risks",
          "data": [
            {
              "key": "Key Risk Factors",
              "value": "Potential legal challenges regarding Standard Contractual Clauses for data transfer."
            },
            {
              "key": "Compliance Costs",
              "value": "Substantial costs involved to comply with healthcare laws and regulations."
            },
            {
              "key": "Consequences of Violations",
              "value": "Potential penalties include fines, civil and criminal penalties, and exclusion from Medicare and Medicaid."
            },
            {
              "key": "Promotional Restrictions",
              "value": "Strict regulations on off-label promotion of products and potential liabilities."
            },
            {
              "key": "Ongoing Regulatory Oversight",
              "value": "Even with approval, products are subject to continuous regulatory requirements."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 65,
          "title": "Regulatory Compliance and Drug Marketing",
          "data": [
            {
              "key": "post-marketing study implications",
              "value": "Post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval."
            },
            {
              "key": "reporting requirements",
              "value": "Reporting of any serious and unexpected adverse events and quality or production problems is required."
            },
            {
              "key": "legislation impact",
              "value": "New legislation on drug safety issues could delay product development or increase costs."
            },
            {
              "key": "advertising restrictions",
              "value": "Promotional communications must comply with legal and regulatory restrictions."
            },
            {
              "key": "NDA changes",
              "value": "Changes to approved products require new applications or approvals."
            },
            {
              "key": "FDA compliance",
              "value": "Manufacturers must comply with cGMP requirements and FDA inspections."
            },
            {
              "key": "unknown problems",
              "value": "Discovery of unknown problems may lead to restrictions or recalls."
            },
            {
              "key": "government investigation",
              "value": "Investigations could generate negative publicity and require significant resources."
            },
            {
              "key": "healthcare reform impact",
              "value": "Healthcare legislative reforms may negatively impact business and operations."
            },
            {
              "key": "pharmaceutical industry focus",
              "value": "The pharmaceutical industry is impacted by legislation aimed at healthcare changes."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 66,
          "title": "Impact of the Affordable Care Act and Related Legislative Changes on the Pharmaceutical Industry",
          "data": [
            {
              "key": "Increased Medicaid rebates",
              "value": "The ACA increased the minimum Medicaid rebates owed by manufacturers."
            },
            {
              "key": "Annual fee on manufacturers",
              "value": "The ACA established an annual nondeductible fee on entities that manufacture or import specified branded drugs."
            },
            {
              "key": "Expansion of the 340B program",
              "value": "The ACA expanded the availability of lower pricing under the 340B drug pricing program."
            },
            {
              "key": "Increased statutory minimum rebates",
              "value": "The ACA increased the minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program."
            },
            {
              "key": "Medicaid coverage expansion",
              "value": "The ACA expanded eligibility criteria for Medicaid programs."
            },
            {
              "key": "Patient-Centered Outcomes Research Institute",
              "value": "Established to oversee comparative clinical effectiveness research."
            },
            {
              "key": "Medicare and Medicaid Innovation Center",
              "value": "Created to test innovative payment and service delivery models."
            },
            {
              "key": "Judicial and Congressional challenges to ACA",
              "value": "There have been challenges to the ACA including bills affecting implementation."
            },
            {
              "key": "Repeals of specific ACA taxes",
              "value": "The Tax Cuts and Jobs Act repealed certain taxes imposed by ACA."
            },
            {
              "key": "Medicare drug plan amendments",
              "value": "The BBA amended the ACA to close the coverage gap in Medicare drug plans."
            },
            {
              "key": "American Rescue Plan Act",
              "value": "Eliminates the statutory Medicaid drug rebate cap starting January 1, 2024."
            },
            {
              "key": "Government scrutiny of pricing",
              "value": "There has been heightened scrutiny of pharmaceutical pricing practices."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 67,
          "title": "Analysis of Legislative Changes Impacting Pharmaceutical Pricing",
          "data": [
            {
              "key": "Executive Orders",
              "value": "Biden administration's executive order on drug pricing."
            },
            {
              "key": "Department of Health and Human Services Action",
              "value": "HHS released a Comprehensive Plan for High Drug Prices."
            },
            {
              "key": "IRA Provisions",
              "value": "HHS directed to negotiate drug pricing and penalize inflation-based increases."
            },
            {
              "key": "Impact Timeline",
              "value": "Provisions begin in fiscal year 2023."
            },
            {
              "key": "State Regulations",
              "value": "Legislatures passing laws to control pharmaceutical pricing."
            },
            {
              "key": "Effect on Revenue",
              "value": "Possible reduction in revenue due to government program reimbursement changes."
            },
            {
              "key": "FDA Oversight",
              "value": "Impact of executive actions on FDA's regulatory capabilities."
            },
            {
              "key": "Potential Costs",
              "value": "Potential increased costs and delays due to new regulations."
            },
            {
              "key": "Foreign Corrupt Practices Act",
              "value": "Business activities subject to FCPA regulations."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 76,
          "title": "Legal Proceedings Overview",
          "data": [
            {
              "key": "Case Name",
              "value": "Gorlamari v. Verrica Pharmaceuticals Inc."
            },
            {
              "key": "Court",
              "value": "U.S. District Court for the Eastern District of Pennsylvania"
            },
            {
              "key": "Plaintiff",
              "value": "Kranthi Gorlamari"
            },
            {
              "key": "Allegations",
              "value": "Defendants violated federal securities laws by failing to disclose certain manufacturing deficiencies."
            },
            {
              "key": "Product Involved",
              "value": "VP-102 drug device"
            },
            {
              "key": "Risk",
              "value": "Concerns about regulatory approval due to disclosed deficiencies."
            },
            {
              "key": "Status",
              "value": "Amended complaint filed on January 12, 2023."
            },
            {
              "key": "Relief Sought",
              "value": "Unspecified compensatory damages and other relief."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "regulatory_litigation",
          "page": 77,
          "title": "Litigation and Claims",
          "data": [
            {
              "key": "Litigation Status",
              "value": "The litigation is still in the early stages, and we intend to vigorously defend ourself against these allegations."
            },
            {
              "key": "Ongoing legal proceedings",
              "value": "Other than stated, we are not currently a party to any material legal proceedings."
            },
            {
              "key": "Potential material adverse effects",
              "value": "We are not aware of any pending or threatened legal proceeding that could have a material adverse effect on our business."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_strategic_restructuring": {
      "value": false,
      "elements": []
    },
    "has_supply_chain_disruptions": {
      "value": true,
      "elements": [
        {
          "type": "supply_chain_disruption",
          "page": 51,
          "title": "Regulatory and Supply Chain Risks in Clinical Trials",
          "data": [
            {
              "key": "FDA Compliance",
              "value": "Ensuring clinical trials adhere to general investigational plans and GCPs."
            },
            {
              "key": "GCP Violation Consequences",
              "value": "Fines, adverse publicity, civil and criminal sanctions."
            },
            {
              "key": "CRO Compliance Issue",
              "value": "Failure to comply may make clinical data unreliable."
            },
            {
              "key": "cGMP Compliance",
              "value": "Required conditions for product used in clinical trials."
            },
            {
              "key": "Conflicts of Interest",
              "value": "Financial relationships with principal investigators may affect data integrity."
            },
            {
              "key": "Supply Chain Risks",
              "value": "Reliance on third parties for product supplies and raw materials."
            },
            {
              "key": "Raw Material Source",
              "value": "Naturally-sourced cantharidin from suppliers in the People's Republic of China."
            },
            {
              "key": "Environmental Risk Factors",
              "value": "Contamination risks, habitat loss for beetles, and diseases."
            },
            {
              "key": "Supplier Performance Risk",
              "value": "Supplier's ability to meet demands may be impaired."
            },
            {
              "key": "Trade Relationship Impact",
              "value": "Deterioration in U.S.-China trade relations may restrict supply."
            },
            {
              "key": "Foreign Exchange Risk",
              "value": "Fluctuations in exchange rates could impact import viability."
            }
          ],
          "currency": "N/A"
        }
      ]
    },
    "has_esg_initiatives": {
      "value": true,
      "elements": [
        {
          "type": "esg_initiative",
          "page": 37,
          "title": "FDA Approval Process and Product Development Challenges",
          "data": [
            {
              "key": "NDA submission",
              "value": "First quarter of 2023"
            },
            {
              "key": "Technology transfer",
              "value": "Piramal Pharma Solutions for VP-102 production"
            },
            {
              "key": "Products under development",
              "value": "VP-102, VP-315, VP-103"
            },
            {
              "key": "Regulatory risks",
              "value": "Potential FDA objections and CRL issuance"
            },
            {
              "key": "Investment",
              "value": "Substantial efforts in developing cantharidin formula and products"
            },
            {
              "key": "Market success factors",
              "value": "Successful development, regulatory approval, commercialization and acceptance by the medical community and patients."
            }
          ],
          "currency": "N/A"
        },
        {
          "type": "esg_initiative",
          "page": 80,
          "title": "FDA Resubmission and Collaboration Agreement",
          "data": [
            {
              "key": "FDA Resubmission Date",
              "value": "January 23, 2023"
            },
            {
              "key": "PDUFA Goal Date",
              "value": "July 23, 2023"
            },
            {
              "key": "NDA for VP-102",
              "value": "Resubmitted"
            },
            {
              "key": "Collaboration Partner",
              "value": "Torii Pharmaceutical Co., Ltd."
            },
            {
              "key": "Upfront Payment",
              "value": "$11.5 million"
            },
            {
              "key": "Phase 3 Trial Start Date in Japan",
              "value": "July 25, 2022"
            },
            {
              "key": "Milestone Payment Triggered",
              "value": "$8.0 million"
            },
            {
              "key": "Additional Potential Payments",
              "value": "$50.0 million in aggregate payments"
            },
            {
              "key": "Collaboration Revenue Recognized in 2022",
              "value": "$1.0 million"
            }
          ],
          "currency": "USD"
        }
      ]
    }
  },
  "currency": {
    "USD": 30,
    "EUR": 8,
    "AUD": 14,
    "CAD": 2
  },
  "sha1": "e1edf72618e9d6ae2e72bb3ac7a9ddc15240e4ef"
}